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cholesterol	 or	 insulin	 sensitivity.	 Additionally,	 anorexia	 nervosa	 and	 obsessive-
compulsive	disorder—highly	genetically	correlated	with	each	other—are	the	only	
psychiatric	 disorders	 that	 share	 genetic	 variants	 with	 accelerometer	 measured	
physical	 activity.	 This	 combination	 of	metabolic	 and	 energy	 homeostasis-related	
genetic	 correlations	 may	 be	 unique	 characteristics	 of	 anorexia	 nervosa	 and	
differentiate	it	from	other	psychiatric	traits.	
This	 new	 understanding	 of	 anorexia	 nervosa	 as	 a	 metabo-psychiatric	
disorder	opens	up	new	avenues	for	future	research	strategies	and	underscores	the	
need	 to	 collect	 large	 international	 samples	 with	 deep	 phenotyping	 of	 not	 only	
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Supplementary	 Table	 S3.	 Stratified	 meta-analyses	 by	 anorexia	 nervosa	 (AN)	
subtype	comparing	female	pre-treatment	cases	with	healthy	controls	(CO)	
Supplementary	 Table	 S4.	 Meta-regression	 of	 female	 pre-treatment	 anorexia	
nervosa	(AN)	vs.	healthy	controls	












Supplementary	 Table	 5.	 Conditional	 and	 joint	 analysis	 (COJO)	 of	 the	 anorexia	
nervosa	genome-wide	significant	variants	for	confirmation	of	independence	





Supplementary	Table	9.	 Comparisons	 of	 genetic	 correlations	 between	 anorexia	
nervosa	subtypes	and	other	phenotypes	














Supplementary	 Table	 16.	 Bidirectional	 generalized	 summary	 data-based	










Supplementary	 Table	 S1.	 Twin-based	 (twin-h2)	 and	 single	 nucleotide	
polymorphism-based	 heritability	 (SNP-h2)	 estimates	 derived	 from	 genome-wide	
association	 studies	 (GWAS)	 for	anorexia	nervosa	 (AN)	and	anthropometric	 traits	
measured	by	bioelectrical	impedance	analysis	of	fat-free	mass	(FFM),	and	body	fat	
percentage	(BF%).	
Supplementary	Table	S2.	 Sex	data	 for	 the	 anorexia	nervosa	 (AN)	 genome-wide	
association	study	(GWAS)	datasets	
Supplementary	 Table	 S3.	 Exclusion	 criteria	 by	 International	 Statistical	
Classification	 of	 Diseases	 (ICD-10),	 British	 National	 Formulary	 (BNF),	 and	 UK	
Biobank	variable	























Supplementary	 Data	 1.	 Inflation	 statistics	 and	 heritability	 estimates	 on	 the	
observed	scale	of	the	genome-wide	association	studies	(GWAS)	




glycemic	 traits,	 and	 physical	 activity	 with	 psychiatric	 and	 behavioural	 traits	
between	females	and	males	
Supplementary	 Data	 4.	 Forward	 generalised	 summary	 data-based	 Mendelian	
randomisation	 (GSMR,	 Zhu.	 et	 al,	 2018)	 of	 phenotypes	 that	 showed	 a	 significant	
genetic	correlation	
Supplementary	 Data	 5.	 Reverse	 generalised	 summary	 data-based	 Mendelian	
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Abstract
Objective: Clinically, anorexia nervosa (AN) presents with altered body composition.
We quantified these alterations and evaluated their relationships with metabolites
and hormones in patients with AN longitudinally.
Method: In accordance with PRISMA guidelines, we conducted 94 meta-analyses on
62 samples published during 1996–2019, comparing up to 2,319 pretreatment, post-
treatment, and weight-recovered female patients with AN with up to 1,879 controls. Pri-
mary outcomes were fat mass, fat-free mass, body fat percentage, and their regional
distribution. Secondary outcomes were bone mineral density, metabolites, and hormones.
Meta-regressions examined relationships among those measures and moderators.
Results: Pretreatment female patients with AN evidenced 50% lower fat mass (mean
difference [MD]: −8.80 kg, 95% CI: −9.81, −7.79, Q = 1.01 × 10−63) and 4.98 kg
(95% CI: −5.85, −4.12, Q = 1.99 × 10−28) lower fat-free mass, with fat mass preferen-
tially stored in the trunk region during early weight restoration (4.2%, 95% CI: −2.1,
Abbreviations: AN, anorexia nervosa; BIA, bioelectrical impedance analysis; DSM, Diagnostic and Statistical Manual of Mental Disorders; DXA, dual-energy X-ray absorptiometry; MD, mean
difference; MRI, magnetic resonance imaging; NOS, Newcastle–Ottawa Scale.
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−6.2, Q = 2.30 × 10−4). While the majority of traits returned to levels seen in healthy
controls after weight restoration, fat-free mass (MD: −1.27 kg, 95% CI: −1.79, −0.75,
Q = 5.49 × 10−6) and bone mineral density (MD: −0.10 kg, 95% CI: −0.18, −0.03,
Q = 0.01) remained significantly altered.
Discussion: Body composition is markedly altered in AN, warranting research into
these phenotypes as clinical risk or relapse predictors. Notably, the long-term altered
levels of fat-free mass and bone mineral density suggest that these parameters
should be investigated as potential AN trait markers.
Resumen
Objetivo: Clínicamente, la anorexia nervosa (AN) se presenta con alteraciones en la
composición corporal. Cuantificamos estas alteraciones y evaluamos lon-
gitudinalmente su relación con metabolitos y hormonas en pacientes con AN.
Método: De acuerdo con las pautas PRISMA, realizamos 94 meta-análisis en 62 muestras
publicadas entre 1996–2019, comparando hasta 2,319 pacientes mujeres en pre-tratamiento,
post-tratamiento, y recuperadas en base al peso con hasta 1,879 controles. Las principales
medidas fueron masa grasa, masa libre de grasa, porcentaje de grasa corporal y su distribución
regional. Las medidas secundarias fueron densidad mineral ósea, metabolitos y hormonas. Las
meta-regresiones examinaron las relaciones entre esas medidas y moderadores.
Resultados: Las pacientes femeninas con AN pre-tratamiento mostraron un 50%
menos de masa grasa (MD: −8.80 kg, CI 95%: −9.81, −7.79, Q = 1.01 × 10–63) y
4.98 kg (CI 95%: −5.85, −4.12, Q = 1.99 × 10–28) menos de masa libre de grasa, con
masa grasa preferentemente almacenada en la región del tronco durante la rec-
uperación temprana del peso (4.2%, CI 95%: −2.1, −6.2, Q = 2.30 × 10–4). Aunque la
mayoría de los rasgos regresaron a los niveles vistos en los controles sanos después
de la restauración del peso, la masa libre de grasa (MD: −1.27 kg, CI 95%: −1.79,
−0.75, Q = 5.49 × 10–6) y la densidad mineral ósea (MD: −0.10 kg, CI 95%: −0.18,
−0.03, Q = 0.01) permanecieron significativamente alteradas.
Discusión: La composición corporal es marcadamente alterada en la AN, lo que gar-
antiza la investigación en estos fenotipos como predictores de riesgo clínico o de
recaída. Notablemente, la alteración a largo plazo de los niveles de masa libre de grasa
y densidad mineral ósea sugieren que estos parámetros debe ser investigados como
potenciales rasgos indicadores de AN.
K E YWORD S
BIA, binge-eating/purging, bioelectrical impedance analysis, body fat percentage, bone, dual-
energy X-ray absorptiometry, DXA, estradiol, fat-free mass, insulin, lean mass, long-term follow-
up, restricting, thyroid, weight restoration
1 | INTRODUCTION
Anorexia nervosa (AN) has one of the highest mortality rates of all psychi-
atric disorders (Chesney, Goodwin, & Fazel, 2014). Clinical observations
show altered body composition (El Ghoch, Calugi, Lamburghini, & Dalle
Grave, 2014; Solmi et al., 2016) accompanied by elevated cholesterol
(Hussain et al., 2019) and greater insulin sensitivity (Ilyas et al., 2018).
However, conclusions are limited by small sample sizes and consequent
mixed findings.
Molecular genetic studies have revealed that individuals with AN
carry genetic variants that increase their liability to AN and concur-
rently predispose them to lower body fat percentage, lower fasting




insulin, and higher high-density lipoprotein cholesterol concentrations,
suggesting that metabolic factors may play an etiological role (Duncan
et al., 2017; Watson et al., 2019). Additionally, longitudinal investiga-
tions of a British birth cohort showed that girls who develop AN later
in life are already underweight at the age of 4 years when compared
to healthy children (Yilmaz, Gottfredson, Zerwas, Bulik, & Micali,
2019), adding evidence for a developmental component.
A systematic review showed that adolescents and adults differ-
ently lose fat tissue when affected by AN, with adolescents losing
more central fat tissue and adults more peripheral fat tissue. During
weight recovery, individuals with AN show emergent central adiposity
which typically attenuates over time (El Ghoch, Calugi, et al., 2014).
These clinical and genetic findings encourage the meta-analytic
reassessment of the role of body composition traits, such as fat mass
and fat-free mass, their regional distribution, and their changes associ-
ated with weight restoration and long-term weight recovery in AN.
Meta-analyses have four major advantages compared to systematic
reviews. Increasing statistical power through pooling results from inde-
pendent samples leads to more precise estimates of the underlying
effect. Meta-analyses estimate the heterogeneity (i.e., inconsistency)
among effect sizes from the individual studies included, which are cru-
cial for the interpretation of the pooled estimates. Meta-regressions are
used to investigate potential moderators of the pooled effect sizes and
the relationships between the outcomes of interest, while extensions of
meta-analytical models can estimate potential publication bias
(Nakagawa, Noble, Senior, & Lagisz, 2017).
The goals of these meta-analyses were to (a) replicate findings from
the systematic review on fat mass; (b) extend the observations by quan-
tifying them; (c) include fat-free mass; (d) include bone mineral content
and density; (e) investigate their associations with each other; and (f) if
possible, relate findings to secondary outcomes, such as metabolic and
hormonal parameters. This analytical approach is aimed at understand-
ing the potential associations between these factors that are known to
be physiologically interrelated. A thorough and rigorous examination of
body composition and related laboratory parameters in individuals with
AN could elucidate some of the physiological changes associated with
this serious disorder, which could lead to more effective medical man-
agement, monitoring, and treatment approaches.
2 | METHOD
2.1 | Search strategy, selection criteria, and data
extraction
Our meta-analysis was conducted according to PRISMA guidelines
(Moher, Liberati, Tetzlaff, Altman, & PRISMA Group, 2009) and pre-
registered (PROSPERO 2018 CRD42018105338) with no changes to
the protocol. We conducted a literature search from June 15, 2018,
until July 15, 2019, using the electronic databases PubMed and Web
of Science with a time limitation starting with articles published after
January 1, 1994—marking the introduction of the Diagnostic and Sta-
tistical Manual of Mental Disorders, 4th Edition (DSM-IV; American
Psychiatric Association, 2013). We used key search terms including
“anorexia nervosa” AND (“body composition” OR “body fat” OR “fat
mass” OR “body fat percentage” OR DXA OR BIA OR “fat free mass”
OR “lean mass”). The search was repeated by coauthors to avoid
selection bias. Furthermore, we screened the references of published
articles and reviews. Our search results, including the selection pro-
cess, are presented in Figure 1 according to PRISMA guidelines. Our
selection criteria are presented in Table 1. In case of multiple publica-
tions deriving from the same study population, we selected the arti-
cles reporting either the largest or the most recent data set. In case of
conflict between these two criteria, large sample size was prioritized.
We extracted the information presented in Table 1 from every identi-
fied study using a standardized data extraction sheet.
The data extraction sheet was based on two previous meta-
analyses (Hussain et al., 2019; Ilyas et al., 2018) and included variables
that were hypothesized to be associated with body composition, hor-
monal, or metabolic measures, including fasting status and period,
medications, stage of the menstrual cycle, or treatments for longitudi-
nal studies. If enough studies reported these variables, we performed
meta-regressions to investigate their associations with our primary
and secondary outcomes.
2.2 | Quality of study assessment (Newcastle–
Ottawa scale)
We used the Newcastle–Ottawa Scale (NOS) to assess the quality of
nonrandomized studies (Wells et al., 2009). Each study is judged on
three broad perspectives: (a) the selection of the study groups; (b) the
comparability of the groups; and (c) the ascertainment of the outcome
of interest for case–control studies. The NOS evaluates these three
quality parameters divided across eight specific items. Each item on
the scale is scored from one point, except for comparability, which
can be adapted to the specific topic of interest to score up to two
points. It has been designed to be used in meta-analyses and system-
atic reviews. For the observational studies, low quality was defined as
NOS score ≤8.0 and high quality as score >8.0 (maximum score 9).
2.3 | Meta-analysis
Inverse variance-weighted meta-analyses for females and males separately
were conducted using the statistical package “meta” and “metafor” in the
open-source software R v3.5.1 (r-project.org). We used additional formulas
to calculate missing values (Hozo, Djulbegovic, & Hozo, 2005; Luo, Wan,
Liu, & Tong, 2018;Wan, Wang, Liu, & Tong, 2014). As effect sizes, we esti-
mated mean differences (MDs) between individuals with AN and controls.
We chose a random-effects model, which assumes that the heterogeneity
in the differences between clinical and control groups is due to both
within-study and between-study variation, as we anticipated differences in
procedures and study populations between studies. We quantified the het-
erogeneity through a restricted maximum-likelihood (REML) approach. For
the analysis of subtypes, posttreatment, and weight-recovered patients
with AN, the control groups from the acutely-ill/pretreatment analysis
were reused because (a) control groups were not measured repeatedly and
(b) none of the studies had separate control groups for each subtype




analysis. Although some studies included covariates in their statistical anal-
ysis (Bratland-Sanda et al., 2010; Bredella et al., 2008; Dellava, Policastro, &
Hoffman, 2009; DiVasta et al., 2007; Fernández-Soto, González-Jiménez,
Chamorro-Fernández, & Leyva-Martínez, 2013; Haas et al., 2005; Karlsson,
Weigall, Duan, & Seeman, 2000; Kosmiski, Schmiege, Mascolo, Gaudiani, &
Mehler, 2014; Maïmoun et al., 2018; Nakahara et al., 2007; Schneider
et al., 1998), we only used raw values without including study-specific
covariates to increase comparability across individual studies. Weight
recovery was defined in accordance with DSM-IV and DSM-5 criteria with
BMI >18.5 kg/m2 or >90% ideal body weight. To correct our primary anal-
ysis for multiple testing, false discovery rate–adjusted Q values were calcu-
lated (Benjamini & Hochberg, 1995).
2.4 | Detection and adjustment for publication bias
The results of meta-analyses can be influenced by publication bias
(i.e., small study effects). This describes the phenomenon when certain
studies have been selected for publication, while others—mostly due
to negative findings—have not been published (Nieminen, Rucker,
Miettunen, Carpenter, & Schumacher, 2007). Through graphical diag-
nosis of asymmetry in funnel plots (Egger, Smith, Schneider, & Minder,
1997) and performing Thompson and Sharp tests (i.e., weighted linear
regressions) that take variation between studies into account
(Thompson & Sharp, 1999), we investigated potential small study
effects or publication bias. If the test resulted in a p value below .05,
we adjusted the pooled effect estimates using a Copas selection
model calculated with the R package “metasens.” The model has two
components: the first component estimates the pooled effect, while
the second estimates a publication probability for each study. A large
correlation between these two components suggests that studies with
more extreme effects were more likely to be published (Copas, 1999;
Copas & Shi, 2000, 2001). The models were iteratively optimized
using two tuning parameters γ0 and γ1. We present four diagnostic
graphics including (a) a funnel plot, (b) a contour plot, (c) a treatment
effect plot, and (d) a p value plot.
2.5 | Investigation of potential moderators through
meta-regression and stratification
To examine the large between-study heterogeneity per meta-
analysis (Table 1), we performed meta-regressions using mixed
effects models included in the R package “meta” that take the het-
erogeneity within and between individual studies into account. The
models were optimized via a REML approach. Through meta-regres-
sion, we investigated whether relevant participant or study charac-
teristics may be associated with the pooled estimates, such as mean
age, the time period of follow-up for longitudinal studies, age at
diagnosis, age at menarche, age at amenorrhea, duration of illness,
percentage of amenorrhea in patients with AN, percentage of medi-
cated patients with AN, percentage of individuals taking
F IGURE 1 PRISMA (Preferred
Reporting Items for Systematic Reviews
and Meta-Analyses) flow diagram of
study selection




contraceptives, body composition measurement method, blood sam-
ple type, body composition parameters, and their differences
between cases and controls.
A second approach to test for potential moderators is stratifica-
tion of the sample into meaningful subgroups and estimation of statis-
tical differences between the pooled estimates per subgroup. We
used this approach and stratified by AN subtype.
3 | RESULTS
3.1 | Results of the search and selection of studies
A total of 1,498 papers published between 1996 and 2019 were iden-
tified by our search terms, and 1,434 (96%) of them were excluded.
No paper published during 1994–1996 fulfilled the inclusion criteria,
and the most common reasons for exclusion apart from not investigat-
ing AN or being a review were (a) no control group (n = 182, 12%);
(b) no main outcome reported (i.e., body composition; n = 75, 5%); and
(c) sample overlap (n = 73, 5%). Detailed exclusion process is pres-
ented in Figure 1. Sixty-four published articles (4%) were included in
our analysis, and we became aware of no additional unpublished sam-
ples after contacting study authors for additional or missing data
(Table S1). The majority of studies focused on female cases and controls
that were sampled consecutively in only 22 of 62 samples (35%,
Table S2) and aged between 13.8 and 31.3 years (Figure S1). As such,
four studies (6%) investigating male AN cases were investigated in a
separate quantitative synthesis and are discussed briefly (El Ghoch, Cal-
ugi, Milanese, Bazzani, & Dalle Grave, 2017; Marra et al., 2019; Misra
et al., 2013; Schorr et al., 2019). Three studies (5%) originated from Aus-
tralasia, 38 (61%) from Europe, 15 (24%) from North America, and
6 (10%) from Asia. Only 13 studies (21%) used the same method of
ascertainment for cases and controls (Table S2). Twenty-nine studies
(47%) investigated inpatients, 8 (13%) outpatients, 2 (3%) a mixture of
both, and 23 studies (37%) did not specify the recruitment or patient-
setting. Twenty-seven studies (44%) comprised collection of blood sam-
ples after a fasting period, whereas only six studies (10%) specified the
fasting period (Bredella et al., 2012; DiVasta et al., 2011; Dostálová,
Sedlácková, Papezová, Nedvídková, & Haluzík, 2009; Estour et al.,
2017; Kaválková et al., 2012; Prioletta et al., 2011). One study (3%) did
not specify whether analyses were performed using plasma or serum
blood (Weinbrenner et al., 2004). Seventeen studies (27%) sampled reg-
ular menstruating participants during the follicular phase of their cycle
(de Alvaro et al., 2007; Dostálová et al., 2009; Estour et al., 2017; Gal-
usca et al., 2015; Germain et al., 2010, 2007, 2016; Grinspoon et al.,
2001; Kaválková et al., 2012; Kirchengast & Huber, 2004; Mayer et al.,
2005, 2009; Nakai, Hamagaki, Takagi, Taniguchi, & Kurimoto, 1999;
Prioletta et al., 2011; Scalfi et. al, 2002; Weinbrenner et al., 2004),
whereas 14 studies (23%) did not provide details about the cycle phase
(Bachmann et al., 2014; Bredella et al., 2012; Delporte, Brichard,
Hermans, Beguin, & Lambert, 2003; DiVasta et al., 2011; Fazeli et al.,
2010; Fernández-Soto et al., 2013; Germain et al., 2010; Gniuli, Liv-
erani, Capristo, Greco, & Mingrone, 2001; Grinspoon et al., 1996; Guo,
Jiang, Liao, Liu, & He, 2013; Haas et al., 2005; Karczewska-Kupczewska
et al., 2010; Maïmoun et al., 2018; Mörkl et al., 2017; Nakahara et al.,
2007; Rigaud, Boulier, Tallonneau, Brindisi, & Rozen, 2010; Tagami
et al., 2004; Tanaka et al., 2003). However, studies were retained to
achieve the largest possible sample size, and––depending on data
availability––meta-regressions were fitted to investigate study charac-
teristics as possible moderators. Originally, 41 studies (66%) were cross-
sectional and 21 were longitudinal (34%, Table S1). However, four of
the longitudinal studies (19%) were analyzed cross-sectional in our
TABLE 1 Selection criteria and extracted data from the original
publications
Selection criteria
a. Studies investigating humans only
b. Any age group
c. No sample overlap
d. Observational cross-sectional or longitudinal studies or
randomized-controlled trials
e. Clinical diagnoses of AN according to the DSM IV–5, or their
revisions (American Psychiatric Association, 2013), or ICD-10
(World Health Organization, 1992)
f. Investigation of body composition by dual-energy X-ray
absorptiometry (Bredella et al., 2010, 2013), bioelectrical impedance
analysis (BIA) (Bonaccorsi et al., 2012; Mattar et al., 2011), dual photon
absorptiometry, or magnetic resonance imaging (Mayer et al., 2005).
g. Published or collected after January 1, 1994 (the year that DSM-IV
was introduced)
h. The study includes a control group or comparison group
i. Publications in any language which could be translated by the
research team: English, German, Swedish, Danish, Spanish
Extracted data
a. Author, publication year
b. Country
c. Sample sizes including gender and age
d. Setting: Inpatient or outpatient
e. Original longitudinal or cross-sectional design
f. Follow-up period if longitudinal
g. Diagnostic criteria: DSM-IV, DSM-IV-TR, DSM-5, or ICD-10
h. Participant screening and exclusion criteria
i. Number of cases: AN pretreatment, posttreatment (ANpost),
recovered from AN (ANrec)
j. Subtype of AN: Restricting (R), binge eating/purging
k. Number of controls
l. Primary outcome variables of body composition: Fat mass, fat-free
mass, body fat percentage, and their regional distribution
m. Secondary outcome variables, which were reported by at least
three studies additional to primary outcomes: Bone mineral
density, glucose, insulin, ghrelin, adiponectin, leptin, insulin-like
growth factor, estradiol, testosterone, cortisol, thyroid-stimulating
hormone, free triiodothyronine, free thyroxine
n. Covariates used in original analysis
o. Fasting and fasting duration
p. Blood sample: Serum, plasma, or unspecified
q. Medication and contraceptives
r. Psychological and additional treatments
s. Outcome was a secondary or primary outcome in the original study
t. Duration of illness
u. Age at diagnosis/onset
v. Age at menarche
w. Percentage of AN cases with amenorrhea and duration of amenorrhea
Abbreviations: AN, anorexia nervosa; ICD-10, International Classification of
Diseases version 10; DSM, Diagnostic and Statistical Manual of Mental
Disorders.




meta-analysis due to missing data. No control group was repeatedly
measured in any of the longitudinal studies.
3.2 | Characteristics of the included studies
We performed four sets of meta-analyses (a) comparing 2,319 pre-
treatment/acutely ill AN patients with 1,879 healthy controls;
(b) comparing 722 post-treatment AN patients with 809 controls;
(c) estimating the change in AN patients (n = 722) from pretreatment
to posttreatment; and (d) comparing 398 weight-recovered individuals
with AN with 660 healthy controls including samples with a long-term
follow-up. The pretreatment AN group comprised 229 individuals suf-
fering from the binge-eating/purging (8% of cases) and 701 from the
restricting subtype (26% of cases). The shortest follow-up period was
5.14 weeks, and the longest was 2 years (Table S1). Twenty studies
(32%) used bioelectrical impedance analysis (BIA) to assess body com-
position, 39 (63%) used dual-energy X-ray absorptiometry (DXA), and
only 3 (5%) utilized magnetic resonance imaging (MRI)––considered to
be the benchmark. Thirty of the 62 studies (48%) investigated body
composition as a primary outcome, whereas it was a secondary out-
come in the remaining studies. The percentage of AN patients with
amenorrhea ranged from 0 to 100%, with 11 studies (18%) not pro-
viding information on menstrual status (Agüera et al., 2015;
Bachmann et al., 2014; Bredella et al., 2012; de Mateo Silleras et al.,
2013; El Ghoch et al., 2012; Gniuli et al., 2001; Iacopino et al., 2003;
Kirchengast & Huber, 2004; Schneider et al., 1998; Tagami et al.,
2004; Tanaka et al., 2003). Thirty-five of 62 studies (56%) did not pro-
vide information on the medication status of AN patients, and
32 (52%) did not indicate whether oral contraceptives were used. In
AN cases, the duration of illness was on average 52.2 months
(SD = 29.4), the duration of amenorrhea 23.0 months (SD = 18.3), and
the age at diagnosis 17.5 years (SD = 3.0). Cases and controls were
well matched for age (Figure S1) and, notably, we did not observe a
difference in age at menarche (Figure S2) or height (Figure S5)
between AN cases and controls.
3.3 | Data and analyses results of meta-analyses and
meta-regressions
Our results from the 94 meta-analyses show that a wide range of
alterations in several key body composition and biochemical measures
exist in AN cases compared with healthy controls (Figure 2 and
Figure S3). For 95% confidence intervals and Q values, heterogeneity
estimates (τ2 and I2), and adjusted estimates due to estimated publica-
tion bias, see Table 2. Detailed forest plots showing each of the
94 meta-analyses are presented as Figures S4–S89 for females and
Figures S90–S95 for males. No differences between restricting and
binge-eating/purging subtype of AN were detected in our meta-
analysis prior to treatment except for total body water (Table S3).
Between-study heterogeneity (I2) was observed in 62 meta-analyses
(70%) and ranged from 52 to 99%, confirming our choice of a
random-effects model. To investigate moderators implicated in het-
erogeneity, we performed 411 meta-regressions (Tables S4–S7). Six
meta-analyses showed funnel plot asymmetry, indicating small study
effects. Therefore, we fitted Copas models to adjust for those effects
and estimate the probable number of unpublished studies (Table 1
and Figures S96–S101).
3.4 | Primary outcomes: Body composition
3.4.1 | Anthropometrics
On average, pretreatment female AN cases had a 15.64 kg (95% CI:
−16.98, −14.30, Q = 5.59 × 10−114) lower body weight and were
0.01 m (95% CI: −0.02, 0.00, Q = 0.02) shorter than healthy controls
(Table S4). After treatment, female AN patients still weighed 4.92 kg
(95% CI: −8.03, −1.81, Q = 1.92 × 10−3) less than healthy controls.
Before treatment, male AN cases weighed 15.48 kg (95% CI: −22.42,
−8.54, Q = 1.80 × 10−5) less than healthy controls and showed no dif-
ferences in height compared with controls.
Correspondingly, the pretreatment BMI difference between
female AN cases and controls was −5.81 kg/m2 (95% CI: −6.25,
−5.38, Q = 2.83 × 10−152), which reduced to −2.10 kg/m2 (95% CI:
−2.53, −1.67, padjCopas < .0001) after treatment as most patients
gained on average 9.93 kg (95% CI: 8.17, 11.68, Q = 2.11 × 10−27)
during treatment. Posttreatment BMI in females was primarily
accounted for by gains in fat mass (βmetareg = 0.81, p = 7.03 × 10−7)
but not through fat-free mass (Table S5). After weight recovery, no
statistically significant MD in BMI between female AN cases and con-
trols was detected. The pretreatment BMI difference between male
AN cases and controls was −5.48 kg/m2 (95% CI: −7.87, −3.09,
Q = 1.80 × 10−5).
3.4.2 | Fat mass
The pretreatment body composition of individuals with AN was signif-
icantly altered. Compared with healthy controls, female AN cases had
8.80 kg (95% CI: −9.81, −7.79, Q = 1.01 × 10−63) lower fat mass,
corresponding to a 13.9% (95% CI: −15.1, −12.6, Q = 5.49 × 10−101;
Figure 3) lower total body mass. Male AN cases had 5.87 kg (95% CI:
−8.98, −2.75, Q = 2.70 × 10−4) lower fat mass, corresponding to 7.5%
(95% CI: −10.8, −4.2, Q = 1.8 × 10−5) lower total body mass. This sug-
gests that body fat was on average 50% lower than in healthy con-
trols. Body fat percentage (βmetareg = −134.53, p = 0.01) and absolute
fat mass (βmetareg = −35.50, p = 2.03 × 10−5) were associated with
whole-body bone mineral density of female AN patients. Absolute fat
mass was also associated with mean age at diagnosis (βmetareg = −1.21,
p = 2.42 × 10−4) in females (Table S4).
After treatment, female AN patients had a 2.37 kg (95% CI: −3.75,
−0.98, Q = 0.002) lower fat mass, which corresponded to 2.5% (95%
CI: −4.3, −0.7, padjCopas = 0.006) less total body mass compared with
healthy controls. Female AN patients gained 6.39 kg (95% CI: 5.13,
7.65, Q = 3.07 × 10−22) fat mass following treatment, which cor-
responded to 10.4% (95% CI: 7.96, 12.87, Q = 6.25 × 10−16) of total
body mass. Posttreatment fat mass (βmetareg = −0.23, p = .01;
Table S5) and gain in fat mass during treatment (βmetareg = −0.20,




p = .02; Table S6) were negatively associated with the presence of
amenorrhea. Following weight recovery, these values fully returned to
levels seen in female healthy controls.
Specifically, compared with healthy controls, female AN patients
had 3.51 kg (95% CI: −4.58, −2.43, Q = 8.07 × 10−10) less trunk fat
mass prior to treatment. In relative terms, however, female AN
patients had lower extremity body fat with 5.4% (95% CI: −8.4, −2.4,
Q = 8.23 × 10−4) less total body mass. The presence of amenorrhea
was significantly associated with lower extremity fat mass
(βmetareg = 0.31, p = .04; Table S4).
After treatment, female AN patients showed a higher trunk body
fat percentage than controls at 12.0% (95% CI: 9.5, 14.4,
padjCopas < 1.00 × 10−4) of total body mass. However, this finding
was strongly influenced by publication bias with an estimated
52 unpublished studies. These results on body composition were not
influenced by height as female and male cases and controls showed
no meaningful difference (i.e., 1 cm pretreatment) or by age as meta-
regressions were nonsignificant (Tables S4–S7).
3.4.3 | Fat-free mass
Overall, the fat-free mass in female AN patients was 4.98 kg (95% CI:
−5.85, −4.12, Q = 1.99 × 10–28; Figure 4) lower before treatment
than in controls, corresponding to 12.3% (95% CI: 8.1, 16.5,
F IGURE 2 Summary plot of all
88 meta-analyses comparing female AN
cases with healthy controls. The plot
shows the Q values (i.e., the false
discovery rate-corrected p values) of
each inverse variance-weighted random-
effects meta-analyses comparing AN
cases pretreatment (purple, n = up to
2,294), posttreatment (light green, n = up
to 722), and after weight recovery (dark
green, n = up to 398) with healthy
controls (n = up to 2,251). Restricted
maximum-likelihood estimator was used
to estimate heterogeneity. Q values are
transformed on the -log10 scale,
multiplied by the sign of the mean
difference (MD) and presented on the x-
axis. Points lying in the yellow area
indicate no statistically significant mean
difference between AN cases and
healthy controls after correction for
multiple testing (i.e., Q > 0.05). Points to
the left of the yellow area indicate a
lower mean value in AN cases than in
controls, whereas points on the right of
the yellow area indicate a higher mean
value in AN cases than in controls. A
dark green point outside the yellow area
indicates a significant difference
between AN cases and controls after
weight recovery (a) The outcomes with
the largest differences between cases
and controls. (b) The less extreme mean
differences. The x-axis was capped at
-log10(Q value) × sign(MD) = −0.25. The
full figure is presented as Figure S3
[Color figure can be viewed at
wileyonlinelibrary.com]










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Q = 3.21 × 10−8) higher proportion of total body mass. In males, fat-
free mass in AN patients was −9.37 kg (95% CI: −12.47, −6.27,
Q = 2.00 × 10−8) lower before treatment than in controls. During treat-
ment, female AN patients gained 2.98 kg (95% CI: 1.74, 4.22,
Q = 6.89 × 10−6) fat-free mass, resulting in 1.82 kg (95% CI: −2.57,
−1.08, Q = 5.41 × 10−6) lower fat-free mass compared to controls. Yet,
weight-recovered female individuals with AN still showed 1.27 kg (95%
CI: −1.79, −0.75, Q = 5.49 × 10−6) lower fat-free mass than controls.
More specifically, pretreatment fat-free mass of the extremities in
females was 1.5% (95% CI: −2.0, −1.0, Q = 8.84 × 10−9) less of total
body mass. After treatment, no marked regional differences in fat-free
mass were observed in female AN patients. However, weight-
recovered female individuals with AN had 0.9% (95% CI: −1.3, −0.5,
Q = 6.30 × 10−5) lower trunk fat-free mass of total body mass than
controls.
Before treatment, we observed a 393.95 kcal/day (95% CI:
−531.04, −256.86, Q = 6.53 × 10−8) lower resting energy expenditure
and 4.77 L (95% CI: −6.13, −3.41, Q = 3.06 × 10−11) less total body
water in female AN patients, which persisted with 3.71 L (95% CI:
−7.07, −0.36, Q = 0.05) after treatment. Both were measured by BIA.
However, resting energy expenditure was not corrected for fat-free
mass or body mass in the original studies, limiting its interpretability.
Before treatment, total body water in females was associated with fat
mass (βmetareg = 0.60, p = .01) and the difference in fat-free mass
between AN cases and controls (βmetareg = 0.48, p = .003).
Before treatment, only the amount of total body water was signifi-
cantly different between female individuals (psubgroup = 1.47 × 10−4)
suffering from the restricting (−5.31 L, 95% CI: −8.15, −2.47,
pR = 2.47 × 10−4, k = 4) or the binge-eating/purging subtype (−11.1 L,
95% CI: −12.04, −10.16, pBP = 5.06 × 10−119, k = 1; Table S3). How-
ever, this finding was limited by only one study investigating the
binge-eating/purging subtype).
3.5 | Secondary outcome: Bone mineral measures
3.5.1 | Bone mineral content and density
Compared with healthy controls, whole-body bone mineral content in
female individuals with AN was 0.16 kg (95% CI: −0.19, −0.12,
Q = 2.73 × 10−20) lower before treatment and 0.09 kg (95% CI: −0.13,
−0.05, Q = 1.63 × 10−5) lower after treatment. Weight-restored female
individuals with AN showed 0.10 kg (95% CI: −0.18, −0.03, Q = 0.01)
lower whole-body bone mineral content compared to controls as they
gained on average 0.05 kg (95% CI: 0.02, 0.09, Q = 0.01) during treat-
ment. The interpretability of these estimates is limited due to the insuffi-
cient follow-up time after weight recovery, exceeding 6 months in only
F IGURE 3 Cross-sectional meta-
analysis of studies reporting body fat
percentage in acutely-ill/pretreatment
female AN patients compared with
healthy controls. Forty-four samples had
the appropriate data for the meta-
analysis with 2,179 AN cases and 1,803
controls. A random-effects meta-analysis
revealed a pooled estimate of the mean
difference (MD: −13.8%; 95% CI: −15.1,
−12.6; Q = 5.49 × 10−101) with the mean
differences ranging from −24.6% to
−5.5%. Heterogeneity between studies
was statistically significant (τ2 = 15.84;
p = 1.40 × 10−98; I2 = 92.8%). C, subtype-
combined sample




two studies (Dellava et al., 2009; Karlsson et al., 2000). The pretreatment
whole-body bone mineral content in females was associated with fat-
free mass (βmetareg = 0.02, p = .02) and fat mass (βmetareg = 0.05, p = .02),
as well as the difference in fat mass between AN patients and controls
(βmetareg = 0.04, p = .002; Table S4). Accordingly, pretreatment whole-
body bone mineral density was 0.03 g/cm2 (95% CI: −0.06, −0.01,
padjCopas = .02) lower in females with AN, but our analysis showed a den-
sity comparable with healthy controls posttreatment. However, only two
studies with 74 AN cases could be included in this analysis.
Before treatment, female AN patients exhibited lower bone min-
eral density in several regions, including hip, lumbar spine, and femoral
neck, with a few being likely to persist after weight recovery. These
findings were associated with duration of illness, the age of AN cases,
and differences in fat mass between cases and controls (Supporting
Information: Secondary Outcomes: Detailed Bone Mineral Measures
and Table S4). Cases and controls in our meta-analyses were age- and
height-matched (Figures S1 and S6); therefore, these variables are
unlikely to be associated with these results.
3.5.2 | Secondary outcomes: Metabolites and
hormones
Exploratory results showed that fasting insulin and glucose concentra-
tions were lower in female AN patients compared with controls but
not associated with fat or fat-free mass, while lower leptin was associ-
ated with fat mass pretreatment. After treatment, these measures
returned to concentrations seen in healthy controls. Before treatment,
thyroid hormones, cortisol, and IGF-1 were lower in female AN
patients, and all three measures were associated with fat mass,
whereas higher cortisol in AN patients was associated with fat-free
mass. For detailed results, see Supporting Information: Secondary
Outcomes: Metabolites and Hormones.
3.5.3 | Methodological moderators
We observed strong between-study heterogeneity (Table 1). To investi-
gate how differences in study design, samples, and measurement
methods may influence the primary and secondary outcomes, we per-
formed an additional set of meta-regressions (Tables S4–S7). The method
of body composition measurement was associated with pretreatment
body fat percentage (βDXA = 3.05, p = .01), fat-free mass (βIsotope Dilu-
tion = −6.18, p = .008), and fat-free mass percentage (βDXA = −8.28,
p = .01), and posttreatment body fat percentage (βDXA = 6.39, p = .005) in
females. Furthermore, femoral neck bone mineral density
(βOutpatient = −0.12, p = 7.65 × 10−4) significantly differed between female
inpatients and outpatients.
4 | DISCUSSION
Our primary meta-analyses showed marked alterations in body com-
position traits in patients with AN before and after treatment. Before
treatment, all three major body compartments—fat, fat-free, and bone
F IGURE 4 Cross-sectional meta-
analysis of studies reporting fat-free mass
content in acutely-ill/pretreatment
female AN patients compared with
healthy controls. Thirty-seven samples
had the appropriate data for the meta-
analysis with 2,319 AN cases and 1,879
controls. A random-effects meta-analysis
revealed a pooled estimate of the mean
difference (MD: −4.98 kg; 95% CI: −5.8,
−4.1; Q = 1.99 × 10−28) with the mean
differences ranging from −12.16 to
0.20 kg. Heterogeneity between studies
was statistically significant (τ2 = 5.92;
p = 1.22 × 10−58; I2 = 90.5%). C, subtype-
combined sample




mass—showed significant reductions that were only partially restored
after treatment. Our meta-analysis estimated ~50% lower body fat in
AN patients which was mirrored by leptin concentrations (Perry &
Shulman, 2018), both of which recovered with treatment. In females,
significant differences were observed in body fat distribution after
treatment as body fat is primarily stored in the trunk. This distribution
pattern may be due to increased insulin sensitivity observed in AN
patients (Ilyas et al., 2018) potentially similar to observations in
healthy individuals after short-term overfeeding (McLaughlin et al.,
2016). We did not detect meaningful or statistically significant differ-
ences in body fat distribution in weight-restored patients, indicating
potential redistribution occurring over longer term follow-up.
A new finding from our meta-analysis is that lower fat mass in
females with AN was correlated with significantly low bone mineral
content and density across the whole body. We speculate that the
hormonal cross-talk between fat and bone tissue may be influencing
this association (El Ghoch et al., 2016; Hawkes & Mostoufi-Moab,
2018), potentially mediated through greater bone marrow adipose tis-
sue observed in AN (Fazeli & Klibanski, 2018; Suchacki & Cawthorn,
2018). Whole-body bone mineral content remained low in weight-
recovered individuals with AN. However, as only two studies followed
patients for longer than 6 months (Dellava et al., 2009; Karlsson et al.,
2000), the duration of follow-up was insufficient to draw firm conclu-
sions because bone mineral mass is slow to normalize. Future studies
should be designed to capture long-term changes. In men with AN, fat
mass and fat-free mass were lower before treatment than in controls.
However, long-term follow-up studies are missing. It has been
reported that short-term weight restoration may normalize body com-
position patterns but could also lead to central adiposity (El Ghoch,
Calugi, et al., 2017), but sample sizes of reports of males are very
small. Additionally, in our analysis alterations in bone mineral mass did
not affect the height of individuals with AN.
Another new finding in our meta-analysis is that we observed a 5 kg
lower fat-free mass in female AN patients, which remained lower even
after treatment and in weight-recovered AN patients, indicating that
current treatment regimens may insufficiently target fat-free mass.
Future studies should also assess muscle mass to identify the compo-
nents of fat-free mass that are most associated with this reduction.
Our secondary outcomes—associations between detailed body
composition and laboratory parameters in AN—were difficult to assess
as only a few published studies reported both outcomes consistently.
Most biochemical alterations were within the range of normal refer-
ence values. However, serious alterations can occur in certain individ-
uals with AN that warrant vigilance by clinicians.
Pretreatment fasting insulin and glucose were reduced in AN
patients independent of fat mass, but both concentrations normalized
following treatment, suggesting that increased insulin sensitivity (Ilyas
et al., 2018) may be a temporary state in AN. The relationship
between AN and insulin sensitivity should be investigated by
euglycemic hyperinsulinemic clamp that showed mixed findings in
very small samples (Castillo, Scheen, Jandrain, & Lefèbvre, 1994; Cas-
tillo, Scheen, Lefebvre, & Luyckx, 1985; Dostálová et al., 2009;
Karczewska-Kupczewska et al., 2010; Pannacciulli et al., 2003;
Prioletta et al., 2011; Zuniga-Guajardo, Garfinkel, & Zinman, 1986).
This approach is supported by epidemiological associations of AN
with type 1 diabetes (Hedman et al., 2018) and its genetic overlap
with fasting insulin (Duncan et al., 2017), type 2 diabetes (Watson
et al., 2019), and insulin sensitivity (Hübel et al., 2018).
AN was associated with body fat percentage-associated low T3-
and T4-syndrome pretreatment, whereas thyroid-stimulating hormone
concentrations were normal. Associations between fat mass and thyroid
hormones have been described before (Kwon et al., 2018); however,
sufficiently powered long-term follow-up studies in AN are absent.
Steroid hormone concentrations were altered showing high corti-
sol, low estradiol, and normal testosterone. Estradiol was negatively
associated with fat-free mass, whereas cortisol was positively associ-
ated with fat mass. These findings suggest that fat-free mass may be a
potential moderator for the return of menses in AN patients and
should be further investigated as most research in recovery of menses
primarily focused on BMI- or weight-related cutoffs (Misra et al.,
2006; Swenne, 2004). Potential reverse causation should also be
taken into account where altered estradiol concentrations may pre-
cede changes in fat-free mass.
Overall, the meta-analyzed study sample was highly selected and
biased as it comprised mostly European females aged between 14 and
31 years, emphasizing the urgent need for studies including diverse
ancestries, such as Asia, South and Central America, and Africa.
Females and males differ in body composition and metabolic charac-
teristics (Karastergiou & Fried, 2017; Link & Reue, 2017), unde-
rscoring the need for more studies on males with AN. Our study
selection was limited by the lack of control groups and underreported
extensive sample overlap. Moreover, control groups were only
measured at baseline in all longitudinal studies, failing to account for
age- and growth-related variation, potentially inflating estimates. Fur-
thermore, no clear-cut and consistent definition of recovery from AN
was used across studies, contributing to heterogeneity (Murray,
Loeb, & Le Grange, 2018). This underscores the necessity of develop-
ing standard definitions of remission and recovery in the eating disor-
ders field (Bardone-Cone, Hunt, & Watson, 2018).
Methodologically, we observed effects of either BIA or DXA on
the measurement of body composition in AN, questioning the compa-
rability of the two methods. Larger, longitudinal validation studies
comparing both methods with whole-body MRI in eating disorders
should be conducted. Additional factors influencing body composition
and biochemical measures, such as menstrual cycle, diurnal changes,
fasting, and preanalytical procedures are summarized in Table 3 and
should be carefully assessed in future studies (Hernandes et al., 2017).
Most importantly, blood comprises approximately 3,500 highly
correlated and interacting proteins (hupo.org; Schwenk et al., 2017)
and 4,600 metabolites (serummetabolome.ca; Psychogios et al.,
2011); therefore, the measurement of single proteins, hormones, or
metabolites is ill-advised. Metabolomics, proteomics, and lipidomics
can capture large amounts of information at adequate statistical
power when used in large samples (Hernandes et al., 2017). Addition-
ally, large epidemiological databases that have measured biomarkers
in childhood, such as the Avon Longitudinal Study of Parents and




Children (ALSPAC; Golding, Pembrey, Jones, & ALSPAC Study Team,
2001) and Generation R (Kooijman et al., 2016), should be harnessed
to determine whether those who go on to develop AN show evidence
for premorbid differences in body composition and biochemical
parameters as has been observed for BMI by Yilmaz et al. (2019).
5 | CONCLUSIONS
Detailed measurement of body composition with simple methods,
such as BIA or DXA, which offers additional information on bone tis-
sue, may help refine our understanding of the nature of AN and its
diagnosis. Our meta-analyses showed that all body compartments
were markedly altered in AN. Individuals with AN presented with 50%
lower fat mass and prolonged recovery periods for fat-free mass and
bone mineral content. The core implication of body composition dif-
ferences are alterations in metabolism, growth, and development.
Although results must be interpreted with caution given small sam-
ples, we found evidence indicating alterations in fasting insulin, thy-
roid, sex, and stress hormones in AN, which appeared to partially
normalize with weight gain and recovery. Large birth cohorts that col-
lected information on eating disorders along with metabolomic infor-
mation offer a rich and exciting opportunity for prospective
investigations that add to our understanding of body composition and
metabolic mechanisms in risk and maintenance of eating disorders.
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TABLE 3 Minimum requirement of variables that should be assessed, reported, and included in statistical analyses of case–control studies
examining anorexia nervosa or other eating disorders to facilitate reproducibility, meta-analysis, and meta-regression
Sampling Sample characteristics
Cases and controls
• Underlying population: community, hospital
• Consecutive sample or selection
• If consecutive, attrition and reasons




• Repeated measurement at follow-up
• Exclusion of current and history of diagnosis (i.e., screening)




• Biological sex and gender
• Height
• Weight
• Body mass index
• Ancestry
• Socioeconomic status & education
Cases
• Age of onset
• Duration of illness
Body composition Menstrual status
• Fat mass
• Fat-free mass
• Bone mineral content and density
• Ideally: Muscle mass
• Measurement method: e.g., MRI, DXA, or BIA
• Physical activity (ideally accelerometer data)
Cases
• Dysmenorrhea or amenorrhea
• Duration of amenorrhea
• Age of menarche
• If menstruating, stage or day of cycle
Controls
• Stage or day of the menstrual cycle (e.g., follicular phase)
Blood sampling Substances
• Blood sample type whole blood, serum, plasma
• Fasting state
• Fasting period




Dose and duration of
• Contraceptives
• Supplements & vitamins
• Medication
! Prescription





aAdapted from Hernandes, Barbas, & Dudzik, 2017. Abbreviations: BIA, bioelectrical impedance analysis; DXA, dual-energy X-ray absorptiometry; MRI,
magnetic resonance imaging.
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Characterized primarily by a low body-mass index, anorexia 
nervosa is a complex and serious illness1, affecting 0.9–4% 
of women and 0.3% of men2–4, with twin-based heritability 
estimates of 50–60%5. Mortality rates are higher than those 
in other psychiatric disorders6, and outcomes are unaccept-
ably poor7. Here we combine data from the Anorexia Nervosa 
Genetics Initiative (ANGI)8,9 and the Eating Disorders Working 
Group of the Psychiatric Genomics Consortium (PGC-ED) and 
conduct a genome-wide association study of 16,992!cases of 
anorexia nervosa and 55,525!controls, identifying eight signif-
icant loci. The genetic architecture of anorexia nervosa mirrors 
its clinical presentation, showing significant genetic correla-
tions with psychiatric disorders, physical activity, and meta-
bolic (including glycemic), lipid and anthropometric traits, 
independent of the effects of common variants associated with 
body-mass index. These results further encourage a reconcep-
tualization of anorexia nervosa as a metabo-psychiatric disor-
der. Elucidating the metabolic component is a critical direction 
for future research, and paying attention to both psychiatric 
and metabolic components may be key to improving outcomes.
The previous PGC-ED GWAS (3,495 cases, 10,982 controls) esti-
mated the common genetic variant-based heritability of anorexia 
nervosa to be around 20%, identified the first genome-wide signifi-
cant locus and reported significant genetic correlations (rg) between 
anorexia nervosa and psychiatric and metabolic/anthropometric 
phenotypes10. These rg analyses pointed toward metabolic etiologi-
cal factors, as they are robust to reverse causation, although they 
could be mediated associations11 or reflect confounding processes12. 
To advance genomic discovery in anorexia nervosa and further 
explore genetic correlations, we combined samples from ANGI8,9, 
the Genetic Consortium for Anorexia Nervosa (GCAN)/Wellcome 
Trust Case Control Consortium-3 (WTCCC-3)13 and the UK 
Biobank14, quadrupling our sample size.
Our GWAS meta-analysis included 33 datasets comprising 
16,992 cases and 55,525 controls of European ancestry from 17 coun-
tries (Supplementary Tables 1–4). We had 80% power to detect 
an odds ratio of 1.09–1.19 (additive model, 0.9% lifetime risk, 
α = 5 × 10−8, minor allele frequency (MAF) = 0.05–0.5). Typical of 
complex-trait GWAS, we observed test statistic inflation (λ = 1.22) 
consistent with polygenicity, with no evidence of significant popula-
tion stratification according to the linkage disequilibrium (LD) inter-
cept and attenuation ratio (Supplementary Note and Supplementary 
Fig. 1). Meta-analysis results were completed for autosomes and the 
X chromosome. We identified eight loci that exceeded genome-wide 
significance (P < 5 × 10−8; Table 1 for loci; Fig. 1 for the Manhattan 
plot; Supplementary Figs. 2 and 3 for the forest and region plots, 
respectively). Many loci were near the threshold for significance, 
and no significant heterogeneity of SNP associations across cohorts 
was detected (P = 0.15–0.64; Supplementary Fig. 2). Conditional 
and joint analysis (GCTA-COJO)15 confirmed independence of the 
lead SNPs within the significant loci (Supplementary Table 5). The 
eight loci were annotated to identify known protein-coding genes 
(Supplementary Table 6; Supplementary Table 7 reports a gene search 
restricted to the single-gene loci). The previously reported PGC-ED 
genome-wide significant variant (rs4622308)10 on 12q13.2 did not 
reach genome-wide significance (P = 7.02 × 10−5); however, between-
cohort heterogeneity was apparent (I2 = 53.7; Supplementary Fig. 4 
and Supplementary Note). The odds ratio was in the same direction 
in 22 (67%) of the cohorts (z = 2.00, P = 0.05, two-tailed test).
Although GWAS findings are informative genome-wide, identi-
fying strong hypotheses about their connections to specific genes is 
not straightforward. We evaluated three ways to connect anorexia 
nervosa-associated loci identified by GWAS to genes: regulatory 
chromatin interactions, relationship to brain expression quantitative 
trait loci (eQTLs; using a superset of CommonMind16 and GTEx17) 
and the standard approach of gene location within a GWAS locus. 
The significant anorexia nervosa-associated loci implicated 121 
brain-expressed genes, 74% by location, 55% by adult brain eQTL 
analysis, 93% by regulatory chromatin interaction and 58 genes by 
all three methods. Supplementary Figure 5 shows the eight GWAS 
loci, GENCODE gene models, adult brain regulatory chromatin 
interactions, brain eQTLs and functional genomic annotations.
Four single-gene loci were confirmed by eQTL analyses, chro-
matin interaction studies or both. These were the locus-intersect-
ing genes CADM1 (locus 2, chromosome 11: 114.9–115.4 Mb, 
Supplementary Fig. 5b), MGMT (locus 4, chromosome 10: 131.2–
131.4 Mb, Supplementary Fig. 5d), FOXP1 (locus 5, chromosome 3: 
70.6–71.0 Mb, Supplementary Fig. 5e) and PTBP2 (locus 6, chromo-
some 1: 96.6–97.2 Mb, Supplementary Fig. 5f). For locus 5, eQTL 
data implicated a distal gene, GPR27. One intergenic locus (locus 
7, chromosome 5: 24.9–25.3 Mb, Supplementary Fig. 5g) had no 
eQTL or chromatin interactions, whereas the other intergenic locus 
(locus 8, chromosome 3: 93.9–95.0 Mb, Supplementary Fig. 5h) 
had eQTL connections to PROS1 and ARL13B. Two complex mul-
tigenic loci had many brain-expressed genes and dense chromatin 
and eQTL interactions that precluded identification of any single 
gene (locus 1, chromosome 3: 47.5–51.3 Mb; locus 3, chromosome 
2: 53.8–54.3 Mb, Supplementary Fig. 5a,c). The clearest evidence 
and connections were for the single-gene loci that intersected 
with CADM1, MGMT, FOXP1 and PTBP2, and we conclude that 
these genes may have a role in the etiology of anorexia nervosa 
(Supplementary Note).






Supplementary Table 8 presents multi-trait analysis (GCTA-
mtCOJO18; conditioning our genome-wide significant SNPs on 
associated variants in GWAS of body-mass index (BMI), type 2 dia-
betes, education years, high-density lipoprotein (HDL) cholesterol, 
neuroticism and schizophrenia. Seven loci appear to be indepen-
dent. Locus 2 on chromosome 11 may not be unique to anorexia 
nervosa and may be driven by genetic variation also associated with 
type 2 diabetes.
Liability-scale SNP heritability (SNP-h2) was estimated using LD 
score regression (LDSC)19,20. Assuming a lifetime prevalence2–4 of 
0.9–4%, SNP-h2 was 11–17% (s.e. = 1%), supporting the polygenic 
nature of anorexia nervosa. Polygenic risk score (PRS) analyses 
using a leave-one-out approach indicated that the PRS captures 
approximately 1.7% of the phenotypic variance on the liability scale 
for discovery P = 0.5. We did not observe differences in polygenic 
architecture between anorexia nervosa subtypes with binge eating 
(2,381 cases, 10,249 controls) or without (2,262 cases, 10,254 con-
trols), or between males (447 cases, 20,347 controls) and females 
(14,898 cases, 27,545 controls) (Methods, Supplementary Note, 
Supplementary Fig. 6 and Supplementary Table 9). Similar to 
females, males in the highest PRS decile had 4.13 (95% confidence 
interval: 2.58–6.62) times the odds of anorexia nervosa than those 
Table 1 | Newly associated genome-wide significant loci for anorexia nervosa
Locus Chromosome Base-pair region Lead SNP Base pair P value A1/
A2




1 3 47,588,253 51,368,253 rs9821797 48,718,253 6.99!×!10−15 A/T 1.17 0.02 0.12 Multigenic 111 NCKIPSD
2 11 114,997,256 115,424,956 rs6589488 115,096,956 6.31!×!10−11 A/T 1.14 0.02 0.13 Single gene 1 CADM1
3 2 53,881,813 54,362,813 rs2287348 54,039,813 5.62!×!10−9 T/C 1.11 0.02 0.16 Multigenic 13 ASB3, 
ERLEC1
4 10 131,269,764 131,463,964 rs2008387 131,448,764 1.73!×!10−8 A/G 1.08 0.01 0.33 Single gene 2 MGMT
5 3 70,670,750 71,074,150 rs9874207 71,019,750 2.05!×!10−8 C/T 1.08 0.01 0.49 Single gene 2 FOXP1
6 1 96,699,455 97,284,455 rs10747478 96,901,455 3.13!×!10−8 T/G 1.08 0.01 0.41 Single gene 2 PTBP2
7 5 24,945,845 25,372,845 rs370838138 25,081,845 3.17!×!10−8 G/C 1.08 0.01 0.56 Intergenic 0 CDH10
8 3 93,968,107 95,059,107 rs13100344 94,605,107 4.21!×!10−8 T/A 1.08 0.01 0.54 Intergenic 2 NSUN3
The results of the GWAS meta-analysis of anorexia nervosa (16,992!cases and 55,525!controls) are shown, in which eight novel genome-wide significant loci were detected. Chromosome and region 
(based on hg19) are shown for SNPs with P!<!1!×!10−5 and LD-r2!>!0.1 with the most associated lead SNP, the location of which is given (base pair). A1/A2 refers to allele 1/allele 2. The odds ratio (OR) and 
s.e. are shown for the association between allele 1 and the phenotype. Frequency indicates the frequency of allele 1 in controls. The number of genes was determined by genomic location, adult brain eQTL, 
regulatory chromatin interactions and MAGMA gene-wise analysis (see Methods). The nearest gene is the nearest gene within the region of LD ‘friends’ of the lead variant (LD-r2!>!0.6!±!500!kb). The 
meta-analysis was restricted to variants with MAF!≥ !0.01 and information quality (INFO) score!≥ !0.70. All loci were confirmed using forest plots based on consistent direction of effect in the majority of 
cohorts and using region plots in which neighboring LD friends were required to show a similar effect. Chromosome X was analyzed but had no loci that reached genome-wide significance. Note, although 
lead variants are annotated to the nearest gene, this does not mean that the gene listed is a causal gene.
Fig. 1 | The Manhattan plot for the primary genome-wide association meta-analysis of anorexia nervosa with 33 case–control datasets (16,992!cases 
and 55,525!controls of European descent). The −log10(P) values for the association tests (two-tailed) are shown on the y axis and the chromosomes 
are ordered on the x axis. Eight genetic loci surpassed the genome-wide significance threshold (−log10(P)!>!7.3; indicated by the line). The lead variant is 
indicated by a diamond, and green circles show the variants in LD. The blue and red colors differentiate adjacent chromosomes.





in the lowest decile. However, confirmation of these results requires 
larger samples.
We tested SNP-based genetic correlations (SNP-rg) with exter-
nal traits using bivariate LDSC19,20. Bonferroni-significant SNP-rg 
assorted into five trait categories: psychiatric and personality, physi-
cal activity, anthropometric traits, metabolic traits and educational 
attainment (Supplementary Table 10). Figure 2 presents Bonferroni-
corrected positive SNP-rg values associated with obsessive compul-
sive disorder (SNP-rg ± s.e. = 0.45 ± 0.08; P = 4.97 × 10−9), major 
depressive disorder (0.28 ± 0.07; P = 8.95 × 10−5), anxiety disor-
ders (0.25 ± 0.05; P = 8.90 × 10−8) and schizophrenia (0.25 ± 0.03; 
P = 4.61 × 10−18). This pattern reflects observed comorbidities 
in clinical and epidemiological studies21,22. The newly identified 
positive SNP-rg association with physical activity (0.17 ± 0.05; 
P = 1.00 × 10−4) encourages further exploration of the refractory 
symptom of pathologically elevated activity in anorexia nervosa23. 
We note that the significant SNP-rg of anorexia nervosa with edu-
cational attainment (0.25 ± 0.03; P = 1.69 × 10−15) and related con-
structs was not seen for IQ24.
Expanding our previous observations10, we present a number of 
metabolic and anthropometric rg with anorexia nervosa that are more 
pronounced than in other psychiatric disorders. We observed signif-
icant negative SNP-rg with fat mass (−0.33 ± 0.03; P = 7.23 × 10−25), 
fat-free mass (−0.12 ± 0.03; P = 4.65 × 10−5), BMI (−0.32 ± 0.03; 
P = 8.93 × 10−25), obesity (−0.22 ± 0.03; P = 2.96 × 10−11), type 2 dia-
betes (−0.22 ± 0.05; P = 3.82 × 10−5), fasting insulin (−0.24 ± 0.06; 
P = 2.31 × 10−5), insulin resistance (−0.29 ± 0.07; P = 2.83 × 10−5) 
and leptin (−0.26 ± 0.06; P = 4.98 × 10−5), and a significant positive 
SNP-rg with HDL cholesterol (0.21 ± 0.04; P = 3.08 × 10−7).
Systems biology analyses of our results revealed notable 
observations (Methods, Supplementary Tables 11–13 and 
Supplementary Figs. 7–15). Gene-wise analysis with MAGMA 
prioritized 79 Bonferroni-corrected significant genes, most within 
the multigenic locus on chromosome 3 (Supplementary Table 11). 
MAGMA indicated an association with NCAM1 (Supplementary 
Table 11), the expression of which increases in response to food 
restriction in a rodent activity-based anorexia nervosa model25. 
Partitioned heritability analysis showed, as with other GWAS26, 
considerable enrichment of SNP-h2 in conserved regions27 (fold 
enrichment = 24.97, s.e. = 3.29, P = 3.32 × 10−11; Supplementary 
Fig. 7). Cell type group-specific annotations revealed that the over-
all SNP-h2 is significantly enriched for tissues of the central ner-
vous system (Supplementary Fig. 8). One biological pathway was 
significant, Gene Ontology (GO): positive regulation of embry-
onic development (32 genes, P = 1.39 × 10−7; Supplementary Table 
12), which contains two Bonferroni-corrected significant genes on 
chromosome 3, CTNNB1 and DAG1. CTNNB1 encodes catenin 
β-1, which is part of adherens junctions and a component of Wnt 
signaling, and DAG1 encodes dystroglycan, a receptor that binds 
extracellular matrix proteins28. DAG1 falls within locus 1 (47.5–
51.3 Mb). This pathway points to a potential role of developmental 
processes in the etiology of this complex phenotype (although this 
is currently speculative). Genes associated with anorexia nervosa 
were enriched for expression in most brain tissues, particularly 
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Fig. 2 | Bonferroni-significant genetic correlations (SNP-rg) between anorexia nervosa and other phenotypes as estimated by LDSC. Only traits with 
significant P values following Bonferroni correction are shown. Error bars show the s.e. Correlations with 447 phenotypes were tested (Bonferroni-
corrected significance threshold P!>!1.11!×!10–4). Complete results are shown in Supplementary Table 10. Insulin resistance was analysed by the homeostatic 
model assessment of insulin resistance (HOMA-IR); UKB, UK Biobank.





the cerebellum, which has a notably high proportion of neurons29 
(Supplementary Fig. 9). Among 24 brain cell types from mouse 
brain, significant enrichment was found for medium spiny neurons 
and pyramidal neurons from hippocampal CA1 (Supplementary 
Fig. 10). Both medium spiny and pyramidal neurons are linked 
to feeding behaviors, including food motivation and reward30,31 
(Supplementary Note). Using PrediXcan (Supplementary Note), 
36 genes were predicted to be differentially expressed in GTEx tis-
sues or blood (Supplementary Table 13), with the expression of 
MGMT predicted to be downregulated in the caudate. We cau-
tiously note that these results represent the first indications of spe-
cific pathways, tissues and cell types that may mediate genetic risk 
for anorexia nervosa.
Because low BMI is pathognomonic of anorexia nervosa, 
we investigated the extent to which genetic variants associated 
with BMI accounted for genetic correlations with metabolic and 
anthropometric traits. First, covarying for the genetic associations 
of BMI (Methods) led to a mild but statistically non-significant 
attenuation of the SNP-rg between anorexia nervosa and fasting 
insulin, leptin, insulin resistance, type 2 diabetes and HDL cho-
lesterol (Supplementary Tables 14, 15), suggesting that anorexia 
nervosa shares genetic variation with these metabolic pheno-
types that may be independent of BMI. Second, we investigated 
bidirectional causality using generalized summary data-based 
Mendelian randomization (GSMR)18. This indicated a signifi-
cant bidirectional causal relationship such that anorexia nervosa 
risk-increasing alleles may increase the risk for low BMI, and 
BMI-lowering alleles may increase the risk of anorexia nervosa 
(Supplementary Table 16). It is important to note that having only 
eight genome-wide significant loci for anorexia nervosa render this 
analysis marginally powered in the direction of anorexia nervosa to 
BMI, although this analysis is well-powered in the direction of BMI 
to anorexia nervosa.
Replication is challenging with GWAS of low-prevalence con-
ditions, such as anorexia nervosa, as replication samples must be 
sufficiently powered to detect the initial findings. We included all 
available samples in our analysis to maximize chances of reach-
ing the GWAS inflection point, after which there might be a linear 
increase in hits32. The PRS leave-one-out analyses provide evidence 
of replication by demonstrating a higher burden of common risk 
variants associated with anorexia nervosa cases, compared with 
controls, across all the cohorts (Supplementary Fig. 16).
In conclusion, we report multiple genetic loci alongside promis-
ing clinical and functional analyses and enrichments. The increased 
sample size in the present GWAS has allowed us to characterize 
more fully the metabolic contribution to anorexia nervosa than our 
previous report10 by revealing significant rg with metabolism-related 
phenotypes, including glycemic and anthropometric traits, and by 
demonstrating that the effect is robust to correction for the effects 
of common variants significantly associated with BMI. Low BMI 
has traditionally been viewed as a consequence of the psychological 
features of anorexia nervosa (that is, drive for thinness and body 
dissatisfaction). This perspective has failed to yield interventions 
that reliably lead to sustained weight gain and psychological recov-
ery7. Fundamental metabolic dysregulation may contribute to the 
exceptional difficulty that individuals with anorexia nervosa have in 
maintaining a healthy BMI (even after therapeutic renourishment). 
Our results encourage consideration of both metabolic and psycho-
logical drivers of anorexia nervosa when exploring new avenues for 
treating this frequently lethal illness.
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Samples and study design. Thirty-three datasets with 16,992 cases of anorexia 
nervosa and 55,525 controls were included in the primary GWAS. We included 
individuals from the PGC-ED Freeze 110, newly collected samples from the 
ANGI8,9, archived samples from the GCAN/WTCCC313, samples from cases of 
anorexia nervosa from the UK Biobank14, and additional controls from Poland. 
Case definitions established a lifetime diagnosis of anorexia nervosa via hospital 
or register records, structured clinical interviews, or online questionnaires based 
on standardized criteria (Diagnostic and Statistical Manual of Mental Disorders 
(DSM) III-R, DSM-IV, International Classification of Diseases (ICD) 8, ICD-9 or 
ICD-10), whereas in the UK Biobank, cases self-reported a diagnosis of anorexia 
nervosa. Controls were carefully matched for ancestry, and some, but not all, 
control cohorts were screened for lifetime eating and/or some or all psychiatric 
disorders. Given the relative rarity of anorexia nervosa, large unscreened control 
cohorts were deemed appropriate for inclusion33.
The cohorts are described in the Supplementary Note. Ethical approvals 
and consent forms were reviewed and archived for all participating cohorts (see 
Supplementary Note for Danish methods). Summary details about ascertainment 
(Supplementary Table 2), the genotyping platforms used (Supplementary Table 3) 
and genotype availability (Supplementary Table 4) are provided.
Statistical analysis. Data processing and analysis were done on the Lisa Compute 
Cluster hosted by SURFsara (http://www.surfsara.nl) and the GenomeDK high-
performance computing cluster (http://genome.au.dk).
Meta-analysis of genome-wide association data. Quality control, imputation, GWAS 
and meta-analysis followed the standardized pipeline of the PGC, Ricopili (Rapid 
Imputation Consortium Pipeline). Ricopili versions used were 2017_Oct_11.002 
and 2017_Nov_30.003. Quality control included SNP and sample quality control, 
population stratification and ancestry outliers, and familial and cryptic relatedness. 
Further information about the Ricopili pipeline is available from the website 
(https://sites.google.com/a/broadinstitute.org/ricopili) and GitHub repository 
(https://github.com/Nealelab/ricopili/tree/master/rp_bin). Further details of the 
quality control procedures can be found in the Supplementary Note.
Imputation. Imputation of SNPs and insertions–deletions was based on the 1000 
Genomes Phase 3 (http://www.internationalgenome.org) data34.
GWAS. GWASs were conducted separately for each cohort using imputed 
variant dosages and an additive model. Covariates nominally associated with the 
phenotype in univariate analysis (P < 0.05) and five ancestry principal components 
were included in the GWAS (Supplementary Table 18). These analyses used the 
tests and methods programmed in the Ricopili pipeline. To the extent that national 
laws and regulations permitted, we examined sample overlap across cohorts by 
performing LD score bivariate regressions and estimating genetic covariance 
intercepts to assess sample overlap19,20 (Supplementary Table 19). Genomic 
inflation factors (λ) of the final datasets indicated no evidence of inflation of the 
test statistics due to population stratification or other sources (Supplementary 
Table 1). The 33 cohorts were meta-analyzed with the Ricopili pipeline, which uses 
an inverse-variance weighted fixed-effect model. We filtered our GWAS results 
with MAF ≥ 0.01 and INFO score ≥ 0.70 (indicating ‘high quality’).
Analysis of chromosome X. Several cohorts in the primary GWAS did not have X 
chromosome variant data, specifically, some GCAN-based cohorts (fre1, ukd1, 
usa1, gns2) and were excluded. Imputation was performed separately from the 
autosomes35. Chromosome X variants in the pseudoautosomal regions were 
excluded before imputation. SNPs exceeding MAF and INFO score thresholds of 
0.01 and 0.70 were retained and analysis was performed with PLINK v1.9 (https://
www.cog-genomics.org/plink2) and Ricopili.
Female-only GWAS. A supplementary GWAS analysis was conducted on females 
only to determine the similarity of the results to the primary GWAS analysis, which 
included both females and males. The cohorts that did not have chromosome X 
variants to verify sex could not be included (fre1, ukd1, usa1, gns2).
Distance- and LD-based clumping. The GWAS results implicate genomic regions 
(loci). To define a locus, first SNPs that met the genome-wide significant threshold 
of P < 5 × 10−8 were identified. Second, clumping was used to convert significant 
SNPs to regions. The SNP with the smallest P value in a genomic window was kept 
as the index SNP and SNPs in high LD with the index SNP defined the left and 
right end of the region (SNPs with P < 0.0001 and r2 > 0.1 within 3-Mb windows). 
Third, partially or wholly overlapping clumps within 50 kb were identified and 
merged into one region. Fourth, only loci with additional evidence of association 
from variants in high LD as depicted by regional plots were retained; furthermore, 
forest plots needed to confirm the associations based on the majority of cohorts. 
Finally, conditional analyses were conducted to identify SNPs with associations 
independent of the top SNP within the genomic section of interest.
Annotation. Genome-wide significant loci were annotated with RegionAnnotator 
(https://github.com/ivankosmos/RegionAnnotator) to identify known protein-
coding genes within loci (Supplementary Table 6).
Conditional and joint analyses. Conditional and joint analyses were conducted 
using GCTA-COJO15. GCTA-COJO investigates every locus with a joint 
combination of independent markers using a genome-wide SNP selection 
procedure. It takes into account the LD correlations between SNPs and runs a 
conditional and joint analysis on the basis of conditional P values. After a model 
optimizing process, the joint effects of all selected SNPs are calculated. The largest 
subsample from our GWAS (sedk) was used to approximate the underlying LD 
structure of the investigated lead SNPs. The conditional regression was performed 
in a stepwise manner using the GCTA software36. We analyzed SNPs that had 
P < 5 × 10−8 (Supplementary Table 5).
Multi-trait-based conditional and joint analyses. To separate marginal effects from 
conditional effects (that is, the effect of a risk factor on an outcome controlling 
for the effect of another risk factor), we performed a multi-trait-based conditional 
and joint analysis (GCTA-mtCOJO)18 using an extension of the GCTA software 
(http://cnsgenomics.com/software/gcta)36 (Supplementary Table 8). This method 
uses summary-level data to perform the conditional analysis. We conditioned the 
results of our anorexia nervosa GWAS on GWAS results for education years37, 
type 2 diabetes38, HDL cholesterol39, BMI (C.H. et al., manuscript in preparation), 
schizophrenia40 and neuroticism41. We again used the individual-level genotype 
data from our largest cohort (sedk) to approximate the underlying LD structure. 
As a first step, the method performs a generalized summary data-based Mendelian 
randomization (GSMR) analysis (http://cnsgenomics.com/software/gsmr) to test 
for causal association between the outcome (that is, anorexia nervosa) and the 
risk factor (for example, schizophrenia). We removed potentially pleiotropic SNPs 
from this analysis by the heterogeneity in dependent instruments (HEIDI) outlier 
method18. Pleiotropy is the phenomenon when a single locus directly affects several 
phenotypes. The power of the HEIDI outlier method is dependent on the sample 
size of the GWAS. Pleiotropic SNPs are defined as the SNPs that show an effect on 
the outcome that significantly diverges from that expected under a causal model. 
Second, the GCTA-mtCOJO method calculates the genetic correlation between the 
exposure and the outcome using LDSC (https://github.com/bulik/ldsc) to adjust 
for genetic overlap19,20. It also uses the intercept of the bivariate LDSC to account 
for potential sample overlap19,20. As a result, GCTA-mtCOJO calculates conditional 
betas, conditional standard errors and conditional P values. Subsequently, we 
clumped the conditional GWAS results using the standard PLINK v.1.942 algorithm 
(SNPs with P < 0.0001 and r2 > 0.1 within 3-Mb windows) to investigate whether 
any of the genome-wide significant loci showed dependency on genetic variation 
associated with other phenotypes. As described previously18, the GCTA-mtCOJO 
analysis requires the estimates of bxy of the covariate risk factors on the target 
risk factor and disease, rg of the covariate risk factors, heritability (h2SNP) for the 
covariate risk factors and the sampling covariance between SNP effects estimated 
from potentially overlapping samples.
eQTL and chromosome conformation capture (Hi-C) interactions. Although GWAS 
findings are informative genome-wide, identifying strong hypotheses about 
their connections to specific genes is not straightforward. The lack of direct 
connections to genes constrains subsequent experimental modeling and efforts 
to develop improved therapeutics. Genomic location is often used to connect 
significant SNPs to genes, but this is problematic because GWAS loci usually 
contain many correlated and highly significant SNP associations over hundreds of 
kilobases. Moreover, the three-dimensional arrangement of chromosomes in cell 
nuclei enables regulatory interactions between genomic regions that are located 
far apart43. Chromosome conformation capture methods, such as Hi-C, enable 
identification of three-dimensional interactions in vivo44,45 and can clarify GWAS 
findings. For example, an intergenic region associated with multiple cancers was 
shown to be an enhancer for MYC through a long-range chromatin loop46,47, 
intronic FTO variants are robustly associated with body mass but influence 
expression of distal genes through long-range interactions48, and Hi-C was used 
previously49 to assess the three-dimensional chromatin interactome in fetal brain 
and connections of some schizophrenia associations to specific genes were found 
in the study.
To gain a better understanding of the three-dimensional organization of 
chromatin in the brain and to evaluate disease relevance, we applied Hi-C50 to 
post-mortem samples (n = 3 samples of the adult temporal cortex). Details on 
methodology, data processing, quality control and statistical models used for these 
analyses have been published elsewhere51. We generated sufficient reads to enable 
a kilobase-resolution map of the chromatin interactome from adult humans. We 
generated tissue RNA-sequencing, total-stranded RNA-sequencing, chromatin 
immunprecipitation followed by sequencing (H3K27ac, H3K4me3 and CTCF) and 
open chromatin data (assay for transpose-accessible chromatin using sequencing; 
ATAC-seq) for the adult brain to help to interpret the Hi-C results. We also 
integrated brain expression and eQTL data from GTEx to aid these analyses. The 
Hi-C analysis is unbiased in that all chromatin interactions that pass a confidence 
threshold are considered when evaluating the associations between SNPs and 
genes (that is, it is not a capture experiment where only candidate SNP-to-gene 
associations are evaluated).
Similar to a previous study49, we used Hi-C data generated from human adult 
brain to identify genes implicated by three-dimensional functional interactomics 





(Supplementary Fig. 5). These Hi-C data (n = 3, anterior temporal cortex) contain 
more than 103,000 high-confidence, regulatory chromatin interactions51. These 
interactions capture the physical proximity of two regions of the genome in brain 
nuclei (anchors, 10 kb resolution), although they are separated by 20 kb to 2 Mb in 
genomic distance. We focused on the regulatory subset of E–P or P–P (E, enhancer; 
P, promoter) chromatin interactions (with P defined by the location of an open 
chromatin anchor near the transcription start site of an adult brain-expressed 
transcript and E defined by the overlap with open chromatin in adult brain 
plus either H3K27ac or H3K4me3 histone marks). The presence of a regulatory 
chromatin interaction from a GWAS locus to a gene provides a strong hypothesis 
about SNP-to-gene regulatory functional interactions.
SNP-based heritability estimation. LDSC software (https://github.com/bulik/ldsc) 
and methods were used to estimate SNP-based heritabilities for each cohort and 
overall19,20. We used precomputed LD scores based on the 1000 Genomes Project 
European ancestry samples34 (directly downloaded from https://github.com/bulik/
ldsc). The liability scale estimate assumed a population prevalence of 0.9–4% for 
anorexia nervosa2,3.
Polygenic risk scoring for within-trait predictions. Polygenic leave-one-dataset-out 
analysis, using PRSice v2.1.352, was conducted in the first instance to identify  
any extreme outlying datasets. In addition, it enabled the evaluation of the 
association between anorexia nervosa PRS and anorexia nervosa risk in an 
independent cohort as a means of replication of the GWAS results. We derived 
a PRS for anorexia nervosa from the meta-analysis of all datasets except for the 
target cohort, and then applied the PRS to the target cohort to predict affected 
status (Supplementary Fig. 16). Logistic regression was performed, including as 
covariates the first five ancestry components and any other principal components 
that were significantly associated with the phenotype in the target cohort, and the 
target cohort was split into deciles based on anorexia nervosa PRS, for which decile 
1, which consisted of those with the lowest anorexia nervosa PRS, served as  
the reference.
Anorexia nervosa subtype analysis. PRS analyses were conducted with anorexia 
nervosa subgroups to investigate prediction of case status across the subtypes. 
For this, we split the cases of anorexia nervosa into two groups based on whether 
binge eating was present. First, GWAS meta-analyses were conducted for anorexia 
nervosa with binge eating compared to controls (2,381 cases and 10,249 controls; 
k = 3 datasets: aunz, chop, usa2) and anorexia nervosa with no binge eating 
compared to controls (2,262 cases and 10,254 controls; k = 3 datasets: aunz, chop, 
usa2). Controls were randomly split between analyses to maintain independence 
(Supplementary Fig. 6). Genetic correlation analysis using LDSC19,20 was conducted 
to examine the potential genetic overlap of the two anorexia nervosa subtypes 
(Supplementary Table 9). Second, using PRSice52, we calculated PRS for each 
anorexia nervosa subtype separately in the three target cohorts for which anorexia 
nervosa subtype data were available. Finally, mean PRS scores were estimated for 
each subtype by cohort after accounting for covariates in R. Subtype phenotyping is 
described in the Supplementary Note.
Males. To assess whether sex-specific differences in genetic risk load exist for 
anorexia nervosa, we calculated PRS, using PRSice52, from a GWAS meta-analysis 
performed on females only (14,898 cases and 27,545 controls) and applied it to a 
male-only target cohort (447 cases and 20,347 controls) to predict affected status.
Genetic correlations in the cross-trait analysis. Common variant-based genetic 
correlation (SNP-rg) analysis measures the extent to which two traits or disorders 
share common genetic variation. SNP-rg between anorexia nervosa and 447 
traits (422 from an internally curated dataset and 25 from LDHub53) were tested 
using GWAS summary statistics using an analytical extension of LDSC19,20. The 
sources of the summary statistics files (PMID, DOI or unpublished results) used 
in the LDSC are provided in Supplementary Table 10. When there were multiple 
summary statistics files available for a trait, significant SNP-rg reported in the main 
text were chosen based on the largest sample size and/or matching ancestry with 
our sample (that is, European ancestry).
Genetic correlations with anorexia nervosa corrected for BMI were carried out 
to investigate whether the observed genetic correlations between anorexia nervosa 
and metabolic phenotypes were attributable to BMI or partially independent. 
We used GCTA-mtCOJO18 to perform a GWAS analysis for anorexia nervosa 
conditioning on BMI using BMI summary data from our UK Biobank analysis 
(described in the next section) to derive anorexia nervosa GWAS summary 
statistics corrected for the common variants genetic component of BMI 
(Supplementary Tables 14, 15).
GWAS of related traits in UK Biobank. Several GWAS analyses were carried out for 
traits using data from the UK Biobank to allow us to investigate body composition 
genetics in healthy individuals without a psychiatric or weight-altering disorder 
or individuals who were taking weight-altering medication. We also used UK 
Biobank data to carry out GWAS of physical activity level, anxiety and neuroticism 
(Supplementary Table 20). For details, see the Supplementary Note.
GSMR analyses. We performed two bidirectional GSMR analyses18 to test for the 
causal association first between BMI and anorexia nervosa, and second between 
type 2 diabetes and anorexia nervosa, using an extension of the GCTA software36 
(Supplementary Table 16). We used the individual-level genotype data from our 
largest cohort (sedk) to approximate the underlying LD structure. We removed 
potentially pleiotropic SNPs from this analysis by the HEIDI outlier method18. 
Pleiotropic SNPs are defined as the SNPs which show an effect on the outcome that 
significantly diverges from the one expected under a causal model. The method 
uses the intercept of the bivariate LD score regression to account for potential 
sample overlap19,20. As a rule of thumb, GSMR requires GWAS to have at least ten 
genome-wide significant hits. We lowered the threshold for this requirement to 
eight SNPs in our analyses of anorexia nervosa as an exposure and BMI or type 
2 diabetes as an outcome. Results, therefore, should be interpreted with caution. 
Moreover, we investigated bidirectional conditional effects between BMI or type 
2 diabetes and anorexia nervosa. We used GCTA-mtCOJO to perform a GWAS 
analysis for anorexia nervosa conditioning on BMI using summary data from 
our UK Biobank analysis or type 2 diabetes using summary data38. Our anorexia 
nervosa GWAS and the BMI and type 2 diabetes GWAS analyses are based on 
independent samples. For BMI, we also reran the GSMR analysis using the 
BMI-adjusted anorexia nervosa GWAS summary data from the GCTA-mtCOJO 
analysis.
Gene-wise analysis. MAGMA v.1.0654 (http://ctg.cncr.nl/software/magma) was 
used to perform a gene-wise test of association with anorexia nervosa based 
on GWAS summary statistics. MAGMA generates gene-based P values by 
combining SNP-based P values within a gene while accounting for LD. To include 
regulatory regions, SNPs are mapped to genes within a 35-kb upstream and 10-kb 
downstream window, and the gene P value is obtained using the multi = snp-wise 
model, which aggregates mean and top SNP association models. We tested 19,846 
ENSEMBL genes, including the X chromosome (Supplementary Table 11). As a 
reference panel for the underlying LD structure, we used 1000 Genomes European 
data phase 334.
Pathway analysis. MAGMA v.1.0654 was used to perform a competitive pathway 
analysis, testing whether genes associated with anorexia nervosa were more 
enriched in a given pathway than all other pathways. The analysis included 
chromosome X. Biological pathways were defined using gene ontology pathways 
and canonical pathways from MSigDB v.6.155, and psychiatric pathways mined 
from the literature. A total of 7,268 pathways were tested (Supplementary Table 12).
Partitioned heritability. Partitioned heritability was investigated using stratified 
LDSC26, which estimates the per-SNP contribution to overall SNP-heritability 
(SNP-h2) across various functional annotation categories of the genome 
(Supplementary Fig. 7). It accounts for linked markers and uses a ‘full baseline 
model’ of 24 annotations that are not specific to any cell type. We excluded the 
MHC region in our analysis. SNP-h2 can be partitioned in two different ways: a 
non-cell type-specific and a cell type-specific manner. Partitioned heritability 
analysis was used to test for cell type-specific enrichment in the GWAS of anorexia 
nervosa among 10 cell type groups: adrenal tissue and pancreas, cardiovascular 
tissue, central nervous system, connective tissue and bone, gastrointestinal tissue, 
immune and hematopoietic tissues, kidney, liver, skeletal muscle and other tissues, 
which includes adipose tissue (Supplementary Fig. 8).
Gene expression. We conducted a series of gene expression analyses as described in 
the Supplementary Note.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
The policy of the PGC is to make genome-wide summary results public. Genome-
wide summary statistics for the meta-analysis are freely downloadable from the 
website of the PGC (http://www.med.unc.edu/pgc/results-and-downloads). 
Individual-level data are deposited in dbGaP (http://www.ncbi.nlm.nih.gov/gap) 
for ANGI-ANZ/SE/US (accession number phs001541.v1.p1) and CHOP/PFCG 
(accession number phs000679.v1.p1). ANGI-DK individual-level data are not 
available in dbGaP owing to Danish laws, but are available through collaboration 
with principal investigators of the Danish institutions. GCAN/WTCCC3 individual-
level data are deposited in EGA (https://www.ebi.ac.uk/ega) (accession number 
EGAS00001000913) with the exception of the Netherlands and USA/Canada; data 
from these countries are available through collaboration with principal investigators 
of institutions in these countries. UK Biobank individual-level data can be applied 
for on the UK Biobank website (http://www.ukbiobank.ac.uk/register-apply).
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Anorexia nervosa (AN) occurs nine times more often in females than in males. Although environ-
mental factors likely play a role, the reasons for this imbalanced sex ratio remain unresolved. AN
displays high genetic correlations with anthropometric and metabolic traits. Given sex differ-
ences in body composition, we investigated the possible metabolic underpinnings of female pro-
pensity for AN. We conducted sex-specific GWAS in a healthy and medication-free subsample
of the UK Biobank (n = 155,961), identifying 77 genome-wide significant loci associated with
body fat percentage (BF%) and 174 with fat-free mass (FFM). Partitioned heritability analysis
showed an enrichment for central nervous tissue-associated genes for BF%, which was more
prominent in females than males. Genetic correlations of BF% and FFM with the largest GWAS
of AN by the Psychiatric Genomics Consortium were estimated to explore shared genomics. The
genetic correlations of BF%male and BF%female with AN differed significantly from each other
(p < .0001, δ = −0.17), suggesting that the female preponderance in AN may, in part, be explained
by sex-specific anthropometric and metabolic genetic factors increasing liability to AN.
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1 | INTRODUCTION
Anorexia nervosa (AN) is one of the most lethal psychiatric disorders
and has established environmental and genetic risk factors (Chesney,
Goodwin, & Fazel, 2014; Keshaviah et al., 2014). Female sex is the
most robust and replicated risk factor, with nine females affected
for each male case observed (Bulik et al., 2006; Micali, Hagberg,
Petersen, & Treasure, 2013; Steinhausen & Jensen, 2015). Although
historic diagnostic criteria for AN may have favored detection in
females (e.g., presence of the amenorrhea criterion), most schemata
did allow for the diagnosis of AN in males (American Psychiatric
Association, 2013; World Health Organization, 1992). The focus of
most work on gender differences in AN has been on sociocultural fac-
tors, such as personal evaluation of physical appearance and social
pressures to be thin (Bakalar, Shank, Vannucci, Radin, & Tanofsky-
Kraff, 2015) although models based on biological and hormonal fac-
tors, such as growth, sex, and appetite-regulating hormone abnormali-
ties have also been posited (Culbert, Racine, & Klump, 2016; Schorr &
Miller, 2017). However, collectively findings to date are not yet able
to account for the widely disparate prevalences by sex.
The marked alterations in body composition, including fat mass
(FM), fat-free mass (FFM), and bone mineral density observed in AN
are clinical characteristics of the illness, but have generally been consid-
ered to be sequelae of starvation (Westmoreland, Krantz, & Mehler,
2016). Females with AN show significantly greater FM deficits than
affected males (Nagata et al., 2017) and, even after recovery, some
individuals do not restore healthy body fat percentages (BF%; El
Ghoch, Calugi, Lamburghini, & Dalle Grave, 2014). Moreover, lower BF
% is a major risk factor for relapse (Bodell & Mayer, 2011). The causes
of these particular sex differences have not yet been fully investigated.
Both AN and body composition as measured by bioelectrical imped-
ance analysis are heritable (Schousboe et al., 2004; Tarnoki et al., 2014;
Table S1). Significant negative single nucleotide polymorphism-based
autosomal genetic correlations (SNP-rg) between AN and body mass
index (BMI) and BF% were observed by the largest GWAS of AN con-
ducted by the Eating Disorders Working Group of the Psychiatric Geno-
mics Consortium (PGC-ED; Duncan et al., 2017; Watson et al., 2018).
This suggests shared etiology between those anthropometric traits and
AN. Furthermore, AN shares common genetic variation with metabolic
traits, such as insulin sensitivity and cholesterol. This revealed, for the
first time, that a component of the genetic risk for AN is related to body
composition and metabolism (Duncan et al., 2017; Hinney et al., 2017).
Phenotypic sex differences in body composition are also present in
the general population; discernible as early as adolescence, females
have on average higher BF% (Flegal et al., 2009), and less visceral adi-
pose tissue and FFM than males (Paus, Wong, Syme, & Pausova, 2017),
partially due to differences in adipocyte metabolism (Cheung & Cheng,
2016; Karastergiou & Fried, 2017; Link & Reue, 2017). Moreover, epi-
demiological findings indicate a female predominance at both tails of
BMI, in extreme obesity (Kelly, Yang, Chen, Reynolds, & He, 2008;
Lovre & Mauvais-Jarvis, 2015) and in AN (Steinhausen & Jensen, 2015).
Recent evidence shows clear biological sex differences in metabolism in
rodent models (Arnold, 2017) and in humans (Mauvais-Jarvis, 2015).
The observed phenotypic sex differences in body composition
across the lifespan are partially due to genetic factors (Table S1 and
Figure S1; Silventoinen et al., 2016, 2017). Heritability estimates from
twin studies (twin-h2) of these epidemiological sex differences unveiled
that twin-h2 estimates of BMI—a proxy of BF%—vary across the life-
span and show sex-specific patterns, most apparent at the age of
13 years, from 20 to 30, and between ages 70 and 80 (Table S1 and
Figure S1; Silventoinen et al., 2016, 2017). Although the twin-h2 varies
somewhat, the specific genetic factors influencing BMI remain stable
from decade to decade postadolescence, whereas environmental
effects appear to change across time, especially in females (Haberstick
et al., 2010). Additionally, several GWAS of proxy measures of BF%
(Heid et al., 2010; Lindgren et al., 2009; Pulit et al., 2018; Randall et al.,
2013; Winkler et al., 2017) and of BF% itself (Kilpeläinen et al., 2011;
Lu et al., 2016) show clear sex differences in genome-wide significant
genomic loci and documented female-specific heterogeneity in the
genomic architecture extensively (for review, see Link & Reue, 2017;
Pulit, Karaderi, & Lindgren, 2017; Small et al., 2018). Furthermore,
studies have shown that BMI GWAS show tissue-specific enrichment
for the central nervous system (CNS; Finucane et al., 2015, 2018),
whereas waist-to-hip ratio adjusted for BMI GWAS showed enrich-
ment for adipose tissue (Finucane et al., 2018).
Convergent epidemiological and genetic findings show that the
regulation of body composition varies between the sexes and is sub-
stantially influenced by both genetic and environmental factors.
The primary goal of this study is to investigate whether a sex-specific
analysis of genetic determinants of body composition may partially
explain the observed female preponderance in AN. We utilize new
GWAS summary statistics from the PGC-ED with about 16,000 cases,
capitalizing on the availability of detailed and highly standardized body
composition measurements and genetic data of 155,961 healthy and
medication-free individuals in the UK Biobank. Together, these
provide a unique opportunity for a powerful investigation of the sex
specificity of the genetic underpinnings of body composition and
psychiatric traits and their relationship with AN.
2 | METHODS
2.1 | Genome-wide association study of AN by the
Eating Disorders Working Group of the Psychiatric
Genomics Consortium
The meta-analysis of GWAS on AN was a combined effort by the AN
Genetics Initiative (Kirk et al., 2017; Thornton et al., 2018) and the




PGC-ED (www.med.unc.edu/pgc) and comprised 33 cohorts from
17 countries (Table S3) with 16,992 AN cases and 55,525 controls
(Watson et al., 2018). The GWAS included 72,358 females (16,531 of
whom are cases) and 24,454 males (460 of whom are cases;
Table S2). The analysis includes additional samples from the Genetic
Consortium for AN, the Wellcome Trust Case Control Consortium
3 (Boraska et al., 2014), and the UK Biobank (Sudlow et al., 2015).
Case definitions established a lifetime diagnosis of AN via hospital or
register records, structured clinical interviews, or online questionnaires
based on standardized criteria—DSM-III-R, DSM-IV, ICD-8, ICD-9, or
ICD-10—(American Psychiatric Association, 2013; World Health
Organization, 1992), whereas in the UK Biobank cases self-reported a
diagnosis of AN (Davis et al., 2018). Quality control, imputation, GWAS,
and meta-analysis followed the standardized pipeline of the PGC, Rapid
Imputation Consortium Pipeline (Ricopili; https://github.com/Nealelab/
ricopili/tree/master/rp_bin). SNPs were excluded if they had a minor
allele frequency (MAF) smaller than 1%, if no call was made in more
than 2% of samples following imputation, if they were imputed with
low confidence (INFO<0.7), or if they deviated substantially from
Hardy–Weinberg equilibrium (controls p < 10−6, cases p < 10−10).
Individuals were excluded if they showed inbreeding coefficients >0.2,
or evidence of DNA contamination. Ancestry outliers were removed
based on plotting of the first two principal components (PCs). The anal-
ysis was performed using imputed variant dosages and an additive
model. The SNP-based heritability (SNP-h2) of AN calculated using
these data was 17% (SE = 1%), suggesting that a substantial fraction of
the heritability of AN stems from common genetic variation across all
autosomes (Watson et al., 2018).
2.2 | GWASs of body composition: Study design and
participants
Our study includes a cross-sectional analysis of the baseline data from
the epidemiological resource UK Biobank (www.ukbiobank.ac.uk; Allen,
Sudlow, Peakman, Collins, & UK Biobank, 2014; Sudlow et al., 2015).
To identify genetic variation associations with BF% and FFM that are
not confounded by illnesses and their downstream effects or
metabolism-changing medication, we applied stringent exclusion cri-
teria (Table S2). Due to this trait-specific medication and illness filter-
ing, the final analysis included 155,961 (45% female) healthy and drug-
free European ancestry participants comprising 32% of the genotyped
UK Biobank participants. European ancestry was defined by 4-means
clustering of the first two PCs from the genetic data (Warren et al.,
2017). Phenotypic characteristics separated by sex are presented in
Table 1. All statistics were calculated in R 3.4.1 if not otherwise stated.
2.3 | Body composition assessment in healthy
participants
Body composition was assessed with a rigorous and highly standardized
protocol by UK Biobank using the same Tanita BC-418 MA machines
(Tanita Corporation, Arlington Heights, IL) for every participant. This
body composition analyzer calculates FFM and FM from raw bioelectri-
cal impedance data, using standard formulas including sex, age, height,
and athleticism. Individuals whose hydration status might be
compromised (e.g., suffering from diabetes mellitus or other endocrine
diseases) were excluded (Table S3). Bioelectrical impedance technology
has been extensively validated (Genton et al., 2003; Kyle et al., 2004; Lu
et al., 2016), and results in more reliable estimates of body adiposity
than BMI for healthy individuals (Mazzoccoli, 2016; Tanamas et al.,
2016). Therefore, bioelectrical impedance analysis is the most feasible
method in very large epidemiological samples, such as the UK Biobank,
compared with proxy measures of adiposity, and does not expose par-
ticipants to radiation unlike dual-energy X-ray absorptiometry.
2.4 | GWASs on body composition
We calculated sex-specific GWAS on residualized BF% and FFM, using
BGENIE v1.2 (Bycroft et al., 2018). Our final analyses included
7,794,483 SNPs and insertion–deletion variants with an MAF >1%,
imputation quality scores >0.8, and that were genotyped, or present in
the Haplotype Reference Consortium (HRC) reference panel used for
imputation by UK Biobank (McCarthy et al., 2016). We used an addi-
tive model on the imputed dosage data provided by UK Biobank, and
residualized phenotypes prior to GWAS for factors related to assess-
ment center, genotyping batch, smoking status, alcohol consumption,
menopause, and for continuous measures of age, and socioeconomic
status (SES) measured by the Townsend deprivation index (Townsend,
1987) as independent variables. We accounted for underlying popula-
tion stratification by also including the first six PCs, calculated on the
genotypes of the European subsample. We then meta-analyzed these
sex-specific GWAS using METAL (http://csg.sph.umich.edu/abecasis/
metal/; Willer, Li, & Abecasis, 2010) using an inverse variance weighted
model with a fixed effect, to obtain sex-combined results. Significantly
associated SNPs (p < 5 × 10−8) were considered as potential index
SNPs. SNPs in LD (r2 > 0.2) with a more strongly associated SNP
within 3,000 kb were assigned to the same locus using Functional
Mapping and Annotation (FUMA; Watanabe, Taskesen, van Bocho-
ven, & Posthuma, 2017). Overlapping clumps additionally were merged
with a second clumping procedure in FUMA merging all lead SNPs with
r2 = 1 to genomic loci. After clumping, independent genome-wide sig-
nificant loci (5 × 10−8) were compared with entries in the NHGRI-EBI
TABLE 1 Phenotypic characteristics of individuals in the analyses
Meta-analyzed Female Male
Number (%) 155,961 70,700 (45%) 85,261 (55%)
Age (years) 54.9 ! 8.1 54.8 ! 8.0 55.0 ! 8.2
Height (cm) 170.4 ! 9.3 163.0 ! 6.2 176.4 ! 6.7
Weight (kg) 78.1 ! 15.1 69.6 ! 12.6 85.1 ! 13.2
BMI (kg/m2) 27.0 ! 4.2 26.2 ! 4.6 27.4 ! 3.8
Waist circumference (cm) 89.4 ! 12.6 82.3 ! 11.3 95.3 ! 10.3
Hip circumference (cm) 102.5 ! 8.1 102.0 ! 9.3 103.0 ! 6.9
Waist-to-hip ratio 0.9 ! 0.1 0.8 ! 0.1 0.9 ! 0.1
Body fat (%) 29.3 ! 8.2 35.3 ! 6.7 24.4 ! 5.5
Fat mass (kg) 23.0 ! 8.5 25.3 ! 9.1 21.2 ! 7.5
FFM (kg) 55.1 ! 11.6 44.4 ! 4.6 63.9 ! 7.4
SES, Townsend
deprivation index
−1.6 ! 2.9 −1.7 ! 2.8 −1.7 ! 2.9
BMI = body mass index; FFM = fat-free mass; SES = socioeconomic
status.
Data are n (%), or mean (SD).




GWAS catalog (MacArthur et al., 2017) using FUMA (Watanabe et al.,
2017). Sex-specific loci are defined as reaching genome-wide signifi-
cance (5 × 10−8) in either females or males while not showing at least
suggestive significance in the opposite sex (5 × 10−6) with differences
in beta estimates that remain significant after Bonferroni correction for
the total number of significant genomic loci.
2.5 | Genome-wide SNP-based heritability and
partitioned heritability
Using BOLT-LMM (Loh et al., 2015) on genotyped, genome-wide, com-
mon genetic variants and linkage disequilibrium score regression
(LDSC) implemented in LDSC v.1.0.0 (Bulik-Sullivan et al., 2015) on
genome-wide summary statistics, we calculated the total phenotypic
variance explained by common autosomal SNPs, SNP-based heritability
(SNP-h2). We included all genotyped and imputed autosomal variants
for BF% and FFM and used the LD score reference files provided with
the software. We tested for differences between the heritabilities by
calculating SE using a block jackknife method implemented into the
software. To identify tissue types associated with BF% and FFM, we
performed a partitioned heritability analysis in LDSC v.1.0.0, ranking
10 cell type groups based on contribution to heritability after control-
ling for the effects of 53 functional annotations (Finucane et al., 2015).
2.6 | Genetic correlations
Using an analytic extension of LDSC (Bulik-Sullivan et al., 2015), we
calculated SNP-based bivariate genetic correlations (SNP-rg) across
the autosomes to examine the genetic overlap between AN and meta-
bolic and psychiatric GWAS summary statistics. First, we calculated
SNP-rgs between anthropometric traits, namely our BF% and FFM
GWASs with GWASs of childhood BMI (~8 years; Felix et al., 2016),
childhood obesity (Bradfield et al., 2012), childhood FFM (Medina-
Gomez et al., 2017), adult FFM (Zillikens et al., 2017), and adolescence
and young adulthood BMI (~15–25 years; Graff et al., 2013), to esti-
mate the genomic overlap of body composition between different
periods of life. Second, we calculated SNP-rgs of these anthropometric
traits across the lifespan with AN.
Additionally, we computed SNP-rgs of AN (Supporting Informa-
tion) with glycemic traits, such as insulin sensitivity assessed by the
insulin resistance homeostatic model assessment (HOMA-IR), fasting
glucose, and insulin concentrations (Lagou, Mägi, & Hottenga, 2018;
Manning et al., 2012; Scott et al., 2012), to investigate potential medi-
ation of the relationship between body fat and AN. Physical activity is
reported to be increased in AN patients (Achamrah, Coëffier, &
Déchelotte, 2016; Shroff et al., 2006); therefore, we estimated the
genetic overlap between physical activity (Hanscombe, 2018, Unpub-
lished, Supporting Information) and AN. We explored the genomic
contribution to the comorbidity of AN with psychiatric disorders and
traits, including major depressive disorder (MDD; Major Depressive
Disorder Working Group of the Psychiatric GWAS Consortium et al.,
2013), anxiety (Purves et al., 2017), schizophrenia (Schizophrenia
Working Group of the Psychiatric Genomics Consortium et al., 2014),
obsessive–compulsive disorder (OCD; International Obsessive Com-
pulsive Disorder Foundation Genetics Collaborative (IOCDF-GC) and
OCD Collaborative Genetics Association Studies (OCGAS), 2018), and
neuroticism (Coleman, 2017, Unpublished, Supporting Information),
as well as educational attainment (Okbay et al., 2016) by calculating
SNP-rgs. Information on all GWAS is presented in Table S4.
2.7 | Sex-specific analyses of genomic determinants
We investigated differences between sexes in heritability and genetic
architecture to identify sex-specific liability driven by genomic factors.
We examined differences (δ) in the SNP-h2 estimates between males
and females using a block jackknife approach (Supporting Information)
and tested whether the SNP-rgs between females and males were dif-
ferent from 1 to identify potential genetic differences related to sex.
We calculated the SNP-rg of the female and male GWASs with AN
separately to investigate the differences in the relationship of these
sex differences with the risk for AN. To test the statistical significance
of all estimates, we calculated their SE and corresponding p value by
applying a block jackknife method, as described and implemented in
LDSC v1.0.0 by Bulik-Sullivan et al. (2015) and in our Supporting
Information.
As a sensitivity analysis, we repeated all SNP-rg analysis with a
female-only GWAS of AN. However, due to the small number of male
AN cases, it was impossible to perform a male-only analysis. All
methods are described in more detail in the Supporting Information.
Stringent multiple testing correction was performed on each analysis,
using matrix decomposition to detect the effective number of tests
and subsequent Bonferroni correction of the p value thresholds.
3 | RESULTS
3.1 | GWAS of AN
The AN GWAS resulted in eight genome-wide significant loci and
showed enrichment for CNS cell types. It genetically correlated with a
broad range of metabolic and psychiatric phenotypes, mirroring clini-
cally observed comorbidity (for details, see Duncan et al., 2017 ; Wat-
son et al., 2018).
3.2 | GWAS of body composition measures in the
UK Biobank
After quality control, we performed sex-stratified association analyses
on the continuous outcomes of BF% and FFM. Minimal inflation due to
population stratification or other systematic biases was indicated by
LDSC intercepts between 1.02 and 1.10 and lambda median statistic
inflation values (λmedian) between 1.18 and 1.59 (Table S4 and
Figure S3a,b). We identified 34 independent loci associated with meta-
analyzed BF% that are not reported to be associated with anthropomet-
ric traits in the GWAS catalog (MacArthur et al., 2017) and replicated
42 independent genome-wide significant results (p < 5 × 10−8) after
LD-based and distance-based clumping (Figure 1, Figure S4a,
Table S5a,b). We identified one male-specific locus in BF% (Table S5a).
The meta-analyzed GWAS of FFM yielded 83 novel loci and replicated
78 genomic risk loci previously associated with anthropometric traits
(Figure 2, Figure S3b, Table S6a,b). We identified 13 male-specific




genomic loci in FFM (Table S6a). All genomic regions, region plots
thereof, their annotations, including nearby protein coding genes (within
100 kb), and previous entries in the GWAS catalog are published on
FUMA (http://fuma.ctglab.nl/browse) entries 20–25. Summary statistics
are available for download www.topherhuebel.com/GWAS.
3.3 | Genome-wide SNP-based and partitioned
heritability
The SNP-h2 for BF% ranged between 29 and 33%, and for FFM
between 43 and 51% (Figure 3), while that for AN is about 17–20%
with an assumed population prevalence of 0.9% (Duncan et al., 2017;
Watson et al., 2018). The SNP-h2 of FFMmale measured by LDSC
was significantly higher than the SNP-h2 of FFMmeta (p < .001,
δSNP-h2 = 5.6%). However, neither the SNP-h2 estimates for BF% nor
for FFM measured by LDSC differed significantly between the sexes.
Partitioned heritabilities can estimate the proportion of the over-
all SNP-h2 that can be attributed to different cell type groups.
BF%female showed an significant enrichment for the CNS cell type
group with 14% of SNPs explaining an estimated 40% of the SNP-h2
(p = .004), whereas BF%male was significantly enriched for the “other”
cell type group that contains adipose tissue with 20% of SNPs explain-
ing an estimated 57% of the SNP-h2 (p = .004; Figure S4a,b). The
FFMfemale and FFMmale were enriched for connective and bone tissue
with 11% of SNPs explaining an estimated 47% of SNP-h2 in both
sexes (pfemale = 6.65 × 10
−6; pmale = 2.29 × 10
−7; Figure S5a,b). The
meta-analyzed FFMboth was also enriched for skeletal muscle with
10% of SNPs explaining an estimated 37% of SNP-h2 (p = .004,
Figure S5c).
3.4 | Genetic correlations of anthropometric traits
across the lifespan
The significant SNP-rg between BF%meta and BMIchildhood was
0.46 (SE = 0.04; p = 6.11 × 10−32) and between BF%meta and
BMIadolescence/young adulthood was 0.48 (SE = 0.05; p = 9.24 × 10−25).
Similarly, FFMchildhood and FFMadulthood showed a significant SNP-rg of
0.69 (SE = 0.10; p = 2.70 × 10−12) and FFMchildhood also correlated
genetically with FFMmeta in our UK Biobank sample (SNP-rg = 0.30;
SE = 0.04; p = 3.24 × 10−12).
BF%meta and FFMmeta correlated genetically (SNP-rg = 0.26; SE =
0.02; p = 3.95 × 10−26). The SNP-rg between BF%female and BF%male
was significantly less than 1 (SNP-rg = 0.89, SE = 0.03; p=1 = .0005),
indicating heterogeneity in the genomic architecture between females
and males (Figure 4).
3.5 | Sex-specific genetic correlations with AN
We calculated SNP-rg between the sex-specific and sex-combined
GWAS with AN to investigate sex differences. The genetic correlation
FIGURE 1 Miami plot for female (red), male (blue), and meta-analyzed (yellow) genome-wide body fat percentage (BF%) associations. Significant
loci from the sex-combined analyses are highlighted in yellow if they also reached genome-wide significance in the sex-specific genome-wide
association studies (GWASs). The genome-wide significance threshold p < 5 × 10−8 is represented by the red horizontal lines.
Chr = chromosome




between BF%female and AN was −0.44 (SE = 0.04; p = 8.28 × 10−27),
whereas that between BF%male and AN was −0.26 (SE = 0.04;
p = 1.04 × 10−13). These SNP-rg were significantly different from each
other (δSNP-rg = −0.17; SE = 0.04; p = 4.23 × 10−5). AN showed a
significant genetic correlation with FFMmeta (SNP-rg = −0.14; SE =
0.03; p = 5.79 × 10−6) Physical activityfemale showed a significant
SNP-rg with AN (SNP-rg = 0.25; SE = 0.06; p = 1.10 × 10−5), but phys-
ical activitymales did not (SNP-rg = 0.10; SE = 0.06; p = .07). However,
this difference was not statistically significant (δSNP-rg = −0.13; SE =
0.07; p = .05; Figure 4) after multiple testing correction.
BMI-adjusted fasting insulin concentrations and AN were geneti-
cally correlated (SNP-rg = −0.24; SE = 0.06; p = 2.31 × 10−5). Fasting
insulinfemale was genetically correlated with AN (SNP-rg = −0.36; SE =
0.07; p = 5.29 × 10−7), but not fasting insulinmale (SNP-rg = −0.16;
SE = 0.05; p = .003). However, this difference in SNP-rg between sexes
did not reach significance (δSNP-rg = −0.19; SE = 0.08; p = .02) after
multiple testing correction. Sex- and age-adjusted insulin resistance
(HOMA-IR) correlated significantly with AN (SNP-rg = −0.29, SE = 0.07;
p = 2.83 × 10−5; Figure 5), but no sex differences were observed.
AN was significantly correlated with MDDfemale (SNP-rg = 0.26;
SE = 0.07; p = 4.00 × 10−4) and anxietymeta (SNP-rg = 0.25; SE = 0.05;
p = 8.90 × 10−8). However, the difference between the male and
female SNP-rg with AN was not significant in MDD (δSNP-rg = −0.004;
FIGURE 2 Miami plot for female (red), male (blue), and meta-analyzed (yellow) genome-wide fat-free mass (FFM) associations. Significant loci
from the sex-combined analyses are highlighted in yellow if they also reached genome-wide significance in the sex-specific genome-wide
association studies (GWASs). The genome-wide significance threshold p < 5 × 10−8 is represented by the red horizontal lines.
Chr = chromosome
FIGURE 3 Sex-specific single nucleotide polymorphism-based
heritability estimates (SNP-h2) for body fat percentage and fat-free
mass calculated by BOLT-LMM (Loh et al., 2015) and linkage
disequilibrium score regression (LDSC; Bulik-Sullivan et al., 2015).
Error bars represent SE. All estimated SNP-h2 were statistically
significant





FIGURE 4 Heatmap of sex-specific bivariate single nucleotide polymorphism-based genetic correlations (SNP-r2g) of body fat percentage, BMI,
fat-free mass, physical activity, and obesity with AN. The strength of the correlation is reflected in the hue. Blue colors are negative SNP-rgs,
meaning that the same genetic variants influence both traits in opposite directions, and red are positive SNP-rgs meaning that the same genetic
variants influence traits in the same direction. Colored squares are significant after correction for multiple comparisons by matrix decomposition
and Bonferroni correction (pBonferroni = .05/10). The SNP-rgs were calculated by linkage disequilibrium score regression (LDSC). AN = anorexia
nervosa; BF% = body fat percentage; BMI = body mass index; FFM = fat-free mass; PA = physical activity; PGC2 = 2nd freeze psychiatric
genomics consortium; UKB = UK Biobank
FIGURE 5 Sex-specific bivariate single nucleotide polymorphism-based genetic correlations (SNP-rg) of fasting glucose, fasting insulin, and insulin
resistance assessed by the HOMA-IR with AN. The SNP-rgs were calculated by linkage disequilibrium score regression (LDSC). Significant SNP-rgs
are marked with an asterisk (*) after correction for multiple comparisons by matrix decomposition and Bonferroni correction (pBonferroni = .05/28).
The error bars depict the SE. Summary statistics for BMI-adjusted HOMA-IR were not available. AN = anorexia nervosa; BMI = body mass index;
HOMA-IR = insulin resistance by homeostatic model assessment





SE = 0.16; p = .98). While the SNP-rg between education years in
females and males was significantly different from 1 (SNP-rg = 0.91,
SE = 0.02; p = 7.99 × 10−5), indicating sex differences, the SNP-rg of
education years with AN did not differ between females and males
(δSNP-rg = −0.02; SE = 0.03; p = .59; Figure 6). As sensitivity analysis,
all SNP-rgs were also calculated with a female only AN GWAS showing
no meaningful differences (Table S8a).
4 | DISCUSSION
The latest GWAS on AN by the PGC-ED presented evidence for a
reconceptualization of AN as a metabo-psychiatric disorder by identi-
fying significant SNP-rgs of AN with a variety of metabolic pheno-
types, including body composition, lipid metabolism, and glycemic
traits (Duncan et al., 2017; Watson et al., 2018). We extended the
findings on the relationship between BF% and AN by replicating that
genomic effects on BF% differ by sex (Heid et al., 2010; Lindgren
et al., 2009; Pulit et al., 2018; Randall et al., 2013; Winkler et al.,
2017) and showing that female-specific effects on BF% have a signifi-
cantly greater genetic correlation with AN (SNP-rg = −0.44; SE = 0.04;
p = 8.28 × 10−27) than male-specific effects on BF% (SNP-rg = −0.26;
SE = 0.04; p = 1.04 × 10−13). This suggests that a specific set of
genomic variation may be differentially active in females and may
increase the liability for AN. The partitioned heritability analyses of
SNP-h2 showed that BF%female was significantly enriched for CNS tis-
sue while BF%male was enriched for adipose tissue, recapitulating prior
findings in sex-combined samples (Finucane et al., 2015, 2018; Willer
et al., 2009). This indicates a sex-specific enrichment for BF% and that
BF% has associated genetic variation underlying its biology thereby
validating the use of bioelectrical impedance analysis to measure body
compartments. Moreover, our findings suggest that different tissues
may be implicated in the regulation of BF% in females and males.
In our analysis of body composition across the lifespan,
BF%childhood, BF%adolescence and young adulthood, and FFMchildhood were not
genetically correlated with AN, whereas BF%adult and FFMadult was.
However, GWASs of BF% and BMI as well as FFM were well correlated
across the lifespan with SNP-rgs of about ~0.60 across childhood, ado-
lescence, young adulthood, and adulthood (Figure 4). This suggests that
a proportion of BF%-associated genomic variation may become opera-
tive at a later age and that this component may be correlated with risk
for AN. This seems to overlap with the period—between 20 and
30 years of age—in which females and males show a significant differ-
ence in the twin-h2 of BMI (Figure S1; Silventoinen et al., 2016, 2017).
Additionally, we estimated SNP-rg of AN with sex-specific GWASs
of physical activity and glycemic traits to investigate potential
moderators and mediators of the relationship between body fat and
AN. Only physical activityfemale and fasting insulinfemale were signifi-
cantly genetically associated with AN. However, the differences
between female and male SNP-rgs were only nominally significant for
both traits and did not survive correction for multiple testing empha-
sizing the need for larger sample sizes to examine sex differences.
In our sex-specific investigation of the contribution of psychiatric
disorders and behavioral traits to AN, genomic variation associated
with MDD in females and OCD in males suggested a possible sex
effect in their SNP-rg with AN, but statistical tests did not confirm this.
Power may be an issue; in particular, the current sample size of the
OCD GWAS is relatively small. Consequently, some of our findings
need to be interpreted cautiously, and this analysis should be repeated
after much larger GWASs are available preferably with >10,000 cases
of each sex. Some GWASs, however, are well powered and although
the SNP-rg of education years between males and females was signifi-
cantly lower than 1—similar to BF%—we did not observe sex differ-
ences in the SNP-rg of education years with AN, suggesting that
metabolic traits may be more likely to contribute to the sex-specific
liability to AN than psychiatric or behavioral phenotypes.
Our investigation was limited by the small proportion of male AN
cases in the primary AN GWAS (Table S2) not allowing for male-only
analyses. However, female-only analyses did not show meaningful dif-
ferences to the sex-combined analyses (Table S8a). We were unable
to include the X chromosome in the investigations as the genotype
or summary level data for several GWASs in the PGC AN GWAS
FIGURE 6 Sex-specific bivariate single nucleotide polymorphism-based genetic correlations (SNP-rg) of probable anxiety disorder (anxiety),
education years, MDD, neuroticism, OCD, and schizophrenia with anorexia nervosa. The SNP-rgs were calculated by linkage disequilibrium score
regression (LDSC). Significant SNP-rgs are marked with an asterisk (*) after correction for multiple comparisons by matrix decomposition and
Bonferroni correction (pBonferroni = .05/28). The error bars depict the SE. The SE of the OCDmale reaches above 1 and has been cut off.
MDD = major depressive disorder; OCD = obsessive–compulsive disorder





meta-analysis were not available to us when the analyses were con-
ducted. However, this should be incorporated in future studies. Most
importantly, compared with prior BMI GWAS, our study benefited
from arguably more homogeneously assessed body composition phe-
notypes, allowing us to differentiate between BF% and FFM more
effectively (Kilpeläinen et al., 2011; Lu et al., 2016). Moreover, we
adjusted for smoking behavior, alcohol consumption, and menopause
and excluded participants taking weight altering medications and par-
ticipants with somatic diseases or psychiatric disorders that affect
body composition, such as cancers, diabetes, and MDD. This is a
unique and important feature of our investigation and substantially
reduced possible confounding of our GWAS.
Conclusion
Our results add further evidence that AN is both a psychiatric and
metabolic disorder and suggest that an age-dependent specific set of
genomic variation may be differentially active in females that influ-
ences body composition, which may also contribute to liability for
AN. Our work could have therapeutic implications, by considering
exploring approaches to using body composition measures or genetic
markers of body composition as predictors of clinical course or
adverse outcome, and as a component of personalized treatment that
considers an individual's propensity to lose therapeutically restored
weight. Some individuals may be at greater risk of relapse, for exam-
ple, when confronted with periods of negative energy balance, and
this could be addressed in personalized treatment and relapse preven-
tion (Bulik, 2016). Sex-specific genetic and biological factors may par-
tially underlie increased risk for AN in females which suggests that
new and focused studies of body composition and metabolism in AN
patients could increase our understanding of AN etiology and
response to treatment.
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This	 chapter,	 investigating	 sex	 differences	 in	 genetic	 correlations	 of	 body	
composition,	 metabolic	 and	 psychiatric	 traits	 across	 17	 psychiatric	 traits,	 is	




I.,	 …	 Breen.	 (in	 press).	 Genetic	 correlations	 of	 psychiatric	 traits	 with	 body	





















































































































































































































Psychiatric/behavioral	trait	 Body	composition	 rg	 se	 p	
Group	1	 	 	 	 	
Anorexia	nervosa	 Body	fat	%	 -0.34	 0.03	 2.09	x	10-27	
Anorexia	nervosa	 Fat-free	mass	 -0.14	 0.03	 5.79	x	10-6	
Education	years	 Body	fat	%	 -0.34	 0.02	 7.11	x	10-60	
Education	years	 Fat-free	mass	 -0.03	 0.02	 0.14	(n.s.)	
OCD	 Body	fat	%	 -0.31	 0.05	 9.82	x	10-10	
OCD	 Fat-free	mass	 -0.12	 0.04	 0.01	(n.s.)	
Schizophrenia	 Body	fat	%	 -0.09	 0.02	 7.30	x	10-6	
Schizophrenia	 Fat-free	mass	 -0.08	 0.02	 2.00	x	10-4	
Group	2	 	 	 	 	
ADHD	 Body	fat	%	 0.30	 0.03	 2.50	x	10-21	
ADHD	 Fat-free	mass	 0.17	 0.03	 3.84	x	10-11	
Smoking	 Body	fat	%	 0.29	 0.03	 3.59	x	10-23	
Smoking	 Fat-free	mass	 0.15	 0.03	 9.94	x	10-8	
Alcohol	dependence	 Body	fat	%	 0.23	 0.06	 2.00	x	10-0	
Alcohol	dependence	 Fat-free	mass	 0.04	 0.05	 0.45	(n.s.)	
Insomnia	 Body	fat	%	 0.23	 0.04	 2.27	x	10-8	
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(LDSC).	 Colored	 bars	 represent	 genetic	 correlations,	 error	 bars	 depict	 standard	
errors	(SE)	and	asterisks	indicate	statistically	significant	genetic	correlations	with	p	
values	less	than	α	=	0.0003.	This	threshold	was	calculated	via	the	identification	of	
the	 number	 of	 independent	 tests	 using	 matrix	 decomposition	 of	 the	 genetic	


















(GSMR)	analyses.	Colors	 represent	 the	 sex	 of	 the	body	composition	 trait:	 red	 for	
female	effects,	blue	for	male	effects,	and	yellow	for	sex-combined	effects.	Error	bars	












































































Body fat % (BF%) Fat mass (FM) Fat−free mass (FFM)
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134	
differently	 due	 to	 the	 size	 of	 the	 effects.	 All	 estimates	 are	 presented	 together	 in	
Supplementary	Fig.	1	on	the	same	scale.	
Panel	D:	Putative	causal	associations	of	exposures	(rows)	body	composition	traits	
(n	 =	 up	 to	 155,961)	 with	 outcomes	 (columns)	 psychiatric	 disorders	 (n	 =	 up	 to	
77,096)	and	behavioral	traits	(n	=	up	to	217,568).	Dots	represent	the	effect	sizes	(as	
measured	by	odds	ratios,	ORs)	of	risk	factors	on	disorders	or	traits.	
Panel	 E:	 The	 Mendelian	 randomization	 results	 for	 body	 composition	 traits	 as	
exposures	on	 the	outcome	years	of	education.	Dots	 represent	 the	effect	 sizes	 (as	
measured	by	betas,	bxy)	on	the	scale	of	the	risk	factors.	












































Sex-specific	 genetic	 correlations	 of	 glycemic	 traits	 (n	 =	up	 to	140,583)	with	 sex-
combined	psychiatric	disorders	(n	=	up	to	77,096)	and	behavioral	traits	(n	=	up	to	
157,355).	The	autosomal	genetic	correlations	were	calculated	by	bivariate	linkage	
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correlations,	 error	 bars	 depict	 standard	 errors	 (SE)	 and	 asterisks	 indicate	
statistically	significant	genetic	correlations	with	p	values	less	than	α	=	0.0002.	This	
threshold	was	calculated	via	the	identification	of	the	number	of	independent	tests	
using	 matrix	 decomposition	 of	 the	 genetic	 correlation	 matrix	 and	 subsequent	























































Fig. 4 Age-dependence of sex-specific genetic correlations across body composition 
and psychiatric traits. 
Sex-specific genetic correlations of body mass index (BMI) and fat-free mass (n = up to 
157,355) with psychiatric disorders (n = up to 77,096) and behavioral traits (n = up to 
157,355) across the lifespan. Participants of the childhood BMI GWAS (green, n = 
























































Time period and sex
Childhood: both









(lighter colors, n = 29,054) were between 15-35 years, participants of the late adulthood 
GWAS (darker colors, n = 155,961) were between 39-75 years old. Overweight in 
childhood (lime green; n = 13,848) was included as an extreme phenotype. The autosomal 
genetic correlations were calculated by bivariate linkage disequilibrium score regression 
(LDSC). Colored bars represent genetic correlations, error bars depict standard errors 
(SE) and asterisks indicate statistically significant genetic correlations with p values less 
than α = 0.0002. This threshold was calculated via the identification of the number of 
independent tests using matrix decomposition of the genetic correlation matrix and 
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a	 metabolic	 component	 of	 anorexia	 nervosa	 that	 is	 partially	 due	 to	 shared	
underlying	 genetics.	 This	 new	 understanding	 of	 anorexia	 nervosa	 as	 a	 metabo-
psychiatric	 disorder	 opens	 up	 new	 avenues	 for	 future	 research	 strategies	 and	
underscores	the	need	to	collect	large	international	samples	with	deep	phenotyping	
of	 not	 only	 psychological	 traits,	 but	 also	metabolomic,	 proteomic,	 and	 lipidomic	
markers	in	anorexia	nervosa	patients.	We	strengthen	the	perspective	that	anorexia	
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Abstract
Eating disorders are complex heritable conditions influenced by both genetic and environmental factors. Given the progress
of genomic discovery in anorexia nervosa, with the identification of the first genome-wide significant locus, as well as
animated discussion of epigenetic mechanisms in linking environmental factors with disease onset, our goal was to conduct a
systematic review of the current body of evidence on epigenetic factors in eating disorders to inform future directions in this
area. Following PRISMA guidelines, two independent authors conducted a search within PubMed and Web of Science and
identified 18 journal articles and conference abstracts addressing anorexia nervosa (n= 13), bulimia nervosa (n= 6), and
binge-eating disorder (n= 1), published between January 2003 and October 2017. We reviewed all articles and included
a critical discussion of field-specific methodological considerations. The majority of epigenetic analyses of eating disorders
investigated methylation at candidate genes (n= 13), focusing on anorexia and bulimia nervosa in very small samples with
considerable sample overlap across published studies. Three studies used microarray-based technologies to examine DNA
methylation across the genome of anorexia nervosa and binge-eating disorder patients. Overall, results were inconclusive
and were primarily exploratory in nature. The field of epigenetics in eating disorders remains in its infancy. We encourage
the scientific community to apply methodologically sound approaches using genome-wide designs including epigenome-
wide association studies (EWAS), to increase sample sizes, and to broaden the focus to include all eating disorder types.
Introduction
Eating disorders are serious illnesses associated with sig-
nificantly reduced health-related quality of life [1, 2]. Our
current understanding of their etiology is piecemeal and the
evidence base for their treatment, especially anorexia ner-
vosa (AN) in adults, is inadequate [3]. Over the past two
decades, family, twin, and adoption studies have robustly
shown that eating disorders reflect the pattern of complex
trait inheritance being influenced by both genetic and
environmental factors. Twin-based heritabilities for AN
range from 48 to 74%, for bulimia nervosa (BN) from 55 to
62%, and for binge-eating disorder (BED) from 39 to 45%
[4]. A genome-wide association study of AN has yielded
the first genome-wide significant locus on chromosome 12
—a chromosomal region previously associated with auto-
immune diseases including type 1 diabetes [5]. AN, fur-
thermore, shows significant genetic correlations with
various psychiatric, personality, and metabolic phenotypes,
including schizophrenia, neuroticism, glucose metabolism,
and lipid metabolism. This panel of findings has encouraged
a reconceptualization of AN as both a metabolic and psy-
chiatric disorder [6]. At the same time, epigenetic
mechanisms have garnered much interest, offering an added
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layer of gene regulatory information, which could link
external and internal environmental stimuli as well as non-
coding genetic variation with transcriptional consequences,
altering downstream phenotypes [4, 7–9]. Together with
enhanced understanding of the genetic variants underlying
heritable disease risk in eating disorders, epigenetics has the
potential to aid in disentangling the molecular genetic
pathways that contribute to the development and progres-
sion of the illnesses.
Epigenetics
In the context of this review, epigenetics refers to various
biochemical mechanisms giving rise to changes in gene
regulation, which are either heritable or characterized by
long-term stability [10]. Biologically, epigenetic mechan-
isms can be categorized into three groups: DNA modifica-
tions, histone modifications, and non-coding RNA (for
details, see Fig. 1). DNA modifications are chemical mod-
ifications that bind to the DNA itself. Histone proteins
constitute the cores around which DNA is wrapped in the
cell nucleus. They can exert an effect on gene regulation by
altering the accessibility of DNA sequences [10]. Finally,
non-coding RNAs—expressed transcripts which do not
code for proteins—have widespread effects on gene reg-
ulation via mechanisms including post-transcriptional
silencing [11, 12] or chromatin remodeling [13].
DNA methylation is the most widely studied epigenetic
mechanism in the context of complex traits thus far and
disease-associated methylomic dysregulation has been
reported for a number of psychiatric disorders, including
schizophrenia [14, 15], Alzheimer’s disease [16, 17], and
autism spectrum disorder [18, 19]. In addition to DNA
methylation, its oxidized derivatives constitute further
DNA modifications, with DNA hydroxymethylation gen-
erating increasing interest in the context of neuropsychiatric
disease, due to its enrichment in the human brain [20, 21].
While historically defined as occurring independent of the
DNA sequence, recent work has provided evidence for
widespread effects of genetic variants on epigenetic states.
In particular, methylation quantitative trait loci (mQTLs)
are increasingly being characterized: single nucleotide
polymorphisms (SNPs) that exert influence on the methy-
lation state of a CpG site, usually in close vicinity to the
SNP [22, 23].
Unlike the genome sequence, epigenetic marks are
dynamic and can vary across cell- and tissue-types, age and
development, and can be subject to environmental stimuli
including medication and stress (Fig. 2). Perhaps most
strikingly, this has been shown for tobacco smoking, which
was found to have considerable effects on DNA methyla-
tion across several genomic regions [24]. Similarly, epige-
netic profiles are highly correlated with chronological age
and an accurate predictor of age has been derived based on
the DNA methylation profiles of only around 300 CpG sites
[25]. In this sense they are more accurately characterized as
intermediate biological phenotypes and are susceptible
Fig. 1 The epigenetic profile of a human cell comprises several epi-
genetic mechanisms: a DNA methylation is the most prominent and
prevalent DNA modification characterized by an addition of a methyl-
group to cytosine in the context of cytosine-guanine dinucleotides (i.e.,
CpG sites). b Histone proteins compact chromosomal DNA in the
nucleus of the cell and regulate gene expression. Histone modifications
are chemical modifications to the N-terminal histone tails, which
extend out of the nucleosome complex. An increasing number of
modifications to amino acids in the histone tails are being identified,
including methylation, acetylation, and phosphorylation. These mod-
ifications are characterized by tissue specificity and are highly corre-
lated with different chromatin states. c Non-coding RNAs are
expressed transcripts that do not code for proteins. They can affect
gene regulation by binding to transcripts and inhibiting their transla-
tion to proteins (i.e., post-transcriptional silencing) or by guiding the
positioning of nucleosomes along the genome and thereby altering
DNA accessibility. Designed by Vinícius Gaio, London, UK
Fig. 2 Potential factors and environmental confounders influencing
epigenetic profiles. The assessment of these factors should ideally be
included in the design of a study investigating epigenetic profiles




to confounding and other problems faced in traditional
observational studies. This phenotypic feature of epigenetic
profiles means that sources of variation or confounding
need to be taken into account in the experimental design
and statistical analyses [26, 27]. For example, if all indivi-
duals in the control group are older than the affected
individuals, an epigenome-wide association study (EWAS)
may detect epigenetic differences between the two groups
related to ageing, rather than differences associated with
disease status.
Several characteristics of eating disorders support
investigation into the potential contribution of epigenetic
factors, including sex differences (i.e., females are ~8 times
more likely to suffer from AN or BN than males) [28],
periods of increased risk of onset (i.e., particularly in
adolescence and young adulthood) [29], and reported
discordance between monozygotic twins [30, 31]. Eating
disorders are associated with early life stress [32] and
emerging evidence links early life stress with epigenetic
profiles [33]. Empirical evidence confirming this association
in humans is limited due to the low availability of
brain tissue and the scarcity of large longitudinal studies
that collect information on early traumatic experiences
and biological samples enabling epigenetic analysis [34].
The largest study of early-life adversity and DNA
methylation in blood published to date identified no sig-
nificant differential methylation [35]. These characteristics
suggest that the interaction of genetic risk factors and
environmental stressors, can contribute to the onset of
eating disorders and make them an excellent target for
the examination of epigenetic effects on appetite regulation
and eating behavior.
New technical advances in genetic and epigenetic
research, including array-based genome-wide analysis
methods, have led to rapid accumulation of evidence in the
field of psychiatric epigenetics and could serve to expedite
understanding of the biology of eating disorders and to
identify more efficient treatment options [36]. Therefore,
we performed a systematic review including a critical
appraisal of the recent body of evidence of epigenetic
research in eating disorders to reflect on past research and
its limitations and offer guidance for future investigations.
Method
Search strategy
Our systematic literature review was conducted according
to PRISMA guidelines [37]. We conducted an exhaustive
literature search from 16.10.2017 until the 30.10.2017 using
the electronic databases PubMed and Web of Science
with a time limitation starting with articles published after
01.01.2003 marking the first published paper on epigenetics
of eating disorders. We used following key search terms
including (anorexia OR bulimia OR “binge-eating disorder”
OR “eating disorder”) AND (epigenetics OR methylation
OR histone OR “non-coding RNA”). The search was
repeated by the co-primary author to avoid selection bias.
Furthermore, we screened the references of published arti-
cles and reviews. Our search results including the selection
process are presented in Fig. 3 according to PRISMA
guidelines.
Selection criteria
Our inclusion criteria were as follows:
a. Studies investigating humans only
b. Any age group
c. Clinical diagnoses of AN, BN, or BED according
to Diagnostic and Statistical Manual of Mental
Disorders versions IV or 5 and their revisions [38]
or International Classification of Diseases [39]
d. Investigation of any type of epigenetic mechanism:
methylation, histone modification, non-coding RNAs
e. Published after 01.01.2003 (date that the first article
on epigenetics of eating disorders appears in the
literature)
f. Study includes a control group or comparison group
g. Publications in any language
Data extraction




c. Sample including gender and age
d. Follow-up period
e. Diagnostic criteria
f. Participant screening and exclusion criteria
g. Number of cases (AN, BN, BED)
h. Number of controls
i. Matching of cases and controls
j. Outcome variables (Genome-wide methylation level,
candidate genes, number of CpG sites)
k. Covariates
l. Tissue
m. Correction for multiple comparison
n. Laboratory methods
o. Limitations




Quality of evidence assessment (GRADE criteria)
We used the GRADE criteria to assess the quality of evi-
dence of each outcome in our review against eight criteria,
including risk of bias, indirectness, inconsistency, impreci-
sion, and publication bias [40]. The quality is graded high,
moderate, low, or very low and reflects the degree of
confidence in the reviewed effects. We assessed the quality
of evidence for the three outcomes based on their study
design: global methylation level, all candidate genes toge-
ther, and EWAS associations.
Results
A total of 178 papers were identified by our search terms.
We excluded 67 studies because they did not cover
eating disorders, six did not investigate humans, 19 were
reviews, one was a book chapter, and three did not
examine epigenetic mechanisms. This resulted in 16
published studies and two conference abstracts on epige-
netics that met our predetermined inclusion criteria
(Fig. 3). One full-text article was a duplicate of a con-
ference abstract, resulting in 17 studies. To our knowledge
these represent all published studies and conference
abstracts investigating epigenetics in eating disorders that
were available at the close of our search in October,
2017. We contacted authors of conference abstracts for
additional information on their studies (Table 1).
Recent body of evidence
To date, 17 studies on the epigenetics of eating disorders
have been published of which four investigated global
DNA methylation levels, 13 investigated candidate genes,
and three used microarray-based technologies to profile
DNA methylation across the human genome. One study
design was longitudinal, but within this study one time
point was selected and analysed cross-sectionally [41].
All other studies were purely cross-sectional in design
and analysis. Studies primarily investigated young adult
females and focused exclusively on DNA methylation
and some also investigated expression levels, but did not
investigate other epigenetic mechanisms, such as histone
modifications or non-coding RNAs (Table 1). The studies
show extensive sample overlap as four studies are part
of the homocysteine and DNA methylation in eating
disorders (HEaD) study [42–45], two studies recruited
inpatients at the Universitätsmedizin Charité Berlin,
Germany [46, 47], and four studies recruited at the
Douglas Institute Eating Disorders Program in Montreal,
Fig. 3 PRISMA flow diagram
of study selection



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Canada [48–51]. Most studies investigated surrogate tis-
sues with regard to their biological hypotheses, including
whole blood, lymphocytes, or buccal cells instead of
brain or metabolic tissue, and did not correct for hetero-
geneity of these tissues. Ten studies discussed the lim-
itations of using surrogate tissues in their articles, two
mentioned the issue, and four did not elaborate on this
limitation (Table 1).
Global DNA methylation levels
Four studies investigated global DNA methylation dif-
ferences in eating disorders. All studies primarily focused
on AN [45, 51–53], with one study also investigating BN
[45]. Two studies reported global hypomethylation in
individuals with AN [45, 53], one study reported global
hypermethylation in AN [51], and one reported no dif-
ference in global DNA methylation levels between AN
cases and controls [52]. Patients suffering from BN
showed no difference in their global DNA methylation
levels compared with controls [45]. Overall the quality
of evidence resulting from these studies was very low
with inconsistent findings of opposite effects (Supple-
mentary Table 1).
Candidate gene studies
Candidate gene studies are hypothesis-driven and investi-
gate DNA methylation in the vicinity of selected genes.
These candidate genes are selected based on prior knowl-
edge, for example, following differences in protein levels
measured in clinical studies assessing patients with AN
or BN. Overall, 13 studies have been published profiling
DNA methylation in candidate gene regions in the context
of eating disorders, twelve of which focus on AN (n = 9)
and BN (n = 6). These twelve studies investigated genes
relating to synaptic transmission [45], endoplasmatic reti-
culum stress response [45], growth hormone signaling [52],
fluid balance [42], the cannabinoid system [43], dopamine
transmission [44, 50, 54], stress response [46, 48], appetite
regulation [46, 49, 54], serotonin transmission [54], and
oxytocin [55]. One methylomic study of candidate genes in
BED has been reported [56, 57]. The study investigated
promoter methylation of SLC1A2, a gene involved in glu-
tamate clearance, in bipolar disorder. The authors found
decreased DNA methylation in bipolar disorder patients
who also suffered from BED, compared to those who were
only affected by bipolar disorder. However, their sample of
patients reporting binge-eating behavior seemed to com-
prise BN and BED cases, rendering the interpretation of the
results ambiguous [56, 57]. All candidate gene studies of
eating disorders are described in detail in Table 1. The
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































sample sizes never exceeding ~120 participants (Supple-
mentary Table 1).
Epigenome-wide association studies (EWAS)
Three EWAS investigated genome-wide DNA methyla-
tion profiles in AN using the Illumina Infinium®
HumanMethylation450 BeadChip. No genome-wide stu-
dies of DNA methylation have been published on other
eating disorders. Booij et al [51] reported 14 differentially
methylated CpG sites comparing 29 AN patients with 15
normal-weight controls. These 14 hypermethylated CpG
sites were annotated to 11 genes (PRDM16, HDAC4,
TNXB, FTSJD2, PXDNL, DLGAP2, FAM83A, NR1H3,
DDX10, ARHGAP1, PIWIL1) [51]. Kesselmeier et al. [30]
reported 51 differentially methylated CpG sites when
comparing 22 AN cases with 24 lean individuals and 81
CpG sites when comparing AN cases with 30 individuals
from a general population sample. They also showed that
54 of the 81 sites exhibited directionally consistent dif-
ferential DNA methylation differences in a comparison of
twins discordant for AN assessed by a binomial sign test
(Table 2). Although the authors report a replication of
hypermethylation previously reported at a CpG site
annotated to TNXB [30, 51], the significance level for this
replication was only suggestive. In this study, controls
recruited from the population were on average sig-
nificantly older than the AN patients potentially con-
founding the results as methylation patterns are age-
dependent [25, 30]. In a conference presentation, Ramoz
et al [41] conducted the only longitudinal investigation of
36 acutely ill AN patients of whom half remitted after one
year. However, the statistical analysis performed was
cross-sectional. No significant differences in DNA
methylation emerged between remitted AN patients and
those patients who were still ill after a follow-up period of
1 year. However, the study did not include a control group
[41]. Two of the three EWAS were followed up by
pathway analyses (Table 2) [41, 51].
Discussion
The current research on epigenetics in eating disorders is
limited and not yet sufficiently mature to draw sound con-
clusions with most evidence of the reviewed studies being of
very low quality. To date, epigenetic research in eating dis-
orders has, to our knowledge, focused exclusively on DNA
methylation, using three different approaches to investigate
disease-associated methylomic variation. First, early DNA
methylation studies measured global methylation levels in
eating disorder cases comparing them with methylation
levels in healthy controls. Second, DNA methylation at
selected candidate genes has been assessed. Third, genome-
wide approaches are applied in the investigation of epigenetic
alterations in EWAS. In general, studies were cross-sectional
and primarily focused on females. Most studies were con-
ducted on surrogate tissue and presented varying degrees of
acknowledgement and discussion of the limitations of using
surrogate tissues in epigenetic epidemiology.
Overall, global methylation study results were incon-
clusive and inconsistent and did not reveal a clear and
replicable global DNA methylation pattern in either AN or
BN. All four studies were small, with the largest study
profiling 32 AN cases and 24 BN cases, substantially lim-
iting the power to detect effects. More generally, global
levels of DNA methylation may not be of much relevance
to epigenetic epidemiology, as they fail to provide infor-
mation on region-specific DNA methylation, and lack the
specificity to associate the dysregulation of biological
pathways with the occurrence of a disease [58]. Even within
the framework of global DNA methylation studies, the
methods employed in these four studies limit the exam-
ination of DNA methylation to either promoter regions (for
Table 2 Epigenome-wide association study (EWAS) follow-on investigations
Author (Year) Multiple testing
correction
Variability filters Follow-up on hits Validation on
different platform
Function of identified sites
Booij (2015) Bonferroni and
False Discovery
Rate (FDR)
Probes needed to have a
standard deviation of at





No Histone acetylation and
RNA modification,





None Average beta value
across all samples







Ramoz (2017) n.a. n.a. Pathway analysis n.a. n.a.
n.a. not available, RNA ribonucleic acid, AN anorexia nervosa




the approaches based on methylation sensitive restriction
enzymes) or LINE1 elements [52], overlooking other parts
of the genome.
Across candidate gene studies, no clear differentially
methylated candidate genes for AN, for BN, or for BED
were robustly identified. Most candidate regions were
only profiled once, and results of repeatedly measured
genes involved in dopamine signaling did not replicate
across studies [44, 50, 54], showing no clear eating
disorder-associated methylomic variation across the
selected candidate genes. In addition to non-replication,
these studies were limited by small sample sizes render-
ing them imprecise: most of the study populations
included on average only 30 cases with two studies
including 64 cases [49, 50]. Furthermore subjects occa-
sionally comprised a mixture of acutely ill and recovered
patients [55] or a mixture of different eating disorders
[56, 57] introducing heterogeneity. This is particularly
concerning as dietary changes, weight changes, and
accompanied alterations of hormonal concentrations
during the recovery process can have a major effect on
epigenetic profiles in individuals with eating disorders.
Further possible confounders are discussed below. In
epigenetics, as in genetics, a general drawback of a can-
didate gene studies is their hypothesis-driven design.
Specific genes are selected for investigation based on
prior knowledge, narrowing the investigation to only a
very limited part of a large system and failing to attend to
the majority of other genomic regions.
In general, hypothesis-free approaches that explore the
whole genome are the gold standard in genetic research.
Genome-wide approaches are applied in the investigation
of common genetic variation (i.e., single nucleotide
polymorphisms, SNPs) in genome-wide association
studies (GWAS) as well as in the examination of epige-
netic alterations in EWAS. EWAS examining CpG sites
at a genome-wide level have identified multiple AN-
associated differentially methylated sites, replicating a
differentially methylated position at TNXB in one inde-
pendent study [51]. However, the hypermethylation at
this CpG site annotated to TNXB only reached suggestive
significance in the replication attempt [30], failing to
survive stringent correction for multiple comparisons. A
false positive finding, therefore, cannot be ruled out.
Statistically, EWAS share similarities with GWAS in
that site-specific associations with a phenotype across a
large number of genomic loci are conducted. These statis-
tical properties limited the findings in EWAS investigating
eating disorders: First, the reported samples never included
more than 29 cases of AN which is far too small to robustly
detect patterns of differential methylation at a genome-wide
scale, i.e., when conducting over 450,000 statistical tests
[59], leading to imprecise estimates of the effects. Second,
multiple testing correction was not always performed
stringently, e.g., when “suggestive” significant results were
reported or examined sites were filtered before or after
analysis based on methylation variability.
As such, many of the EWAS included above were
labeled as pilot studies by the authors and provide moti-
vation for further investigation, and are a springboard to
launch full-scale projects with larger sample sizes and
careful study design, data collection, and analysis. Future
studies will also require replication in independent sam-
ples and should adhere to stringent methodological cri-
teria, including multiple testing correction, no subjective




One of the primary goals of future epigenetic investiga-
tions of eating disorders should be to increase sample
sizes by international collaborations to improve the
power to detect effects, even when effect sizes are small.
Recent epigenetic studies of other psychiatric disorders
and environmental exposures have examined epigenetic
differences in samples comprising thousands of partici-
pants and notably, replicated successes have been docu-
mented for a number of exposures and diseases including
tobacco smoking [24], C-reactive protein levels in
serum blood [60], and Alzheimer’s disease [16, 17].
While several large consortium efforts have led to
advances in characterizing baseline human tissue epi-
genomes [10, 61, 62], this is rarely extended to the
realm of epigenetic epidemiology in complex diseases.
Unique challenges do exist in conducting large-scale
collaborative epigenetic studies. Combining raw data
(i.e., mega-analytic approaches) in epigenetics is pro-
blematic because technical variation in the data stemming
from different laboratories and procedures (i.e., batch
effects) has substantial impact on overall epigenomic
profiles and can be insufficiently controlled for by post-
hoc statistical or computational approaches [63, 64].
Nonetheless, approaches in which each site generates a
sufficiently large sample under nearly identical conditions
that can later be meta-analyzed are feasible [27]. Alter-
natively, consistent sampling at different study sites
including careful preanalytic sample collection and pro-
cessing followed by analysis in a central laboratory
could prevent many of the aforementioned technical
issues. However, this approach is only feasible if all
study sites meticulously follow the same protocol
regarding tissue sampling, sample handling, and pheno-
typing of participants to control for possible confounders




across study sites. This kind of pooling approach tends
to be complicated by challenges associated with sample
storage, transportation, and loss.
Statistical methods
As with any genome-wide investigation, the large number
of tests performed requires special considerations for
statistical analysis. Most importantly, it is essential to
correct for the number of tests performed. The latest
generation of DNA methylation arrays can simulta-
neously quantify epigenetic profiles at up to 850.000 CpG
sites. An EWAS then tests for associations between a
phenotype of interest and DNA methylation at each
of these sites. Each of the 850.000 tests has a small
probability of reporting a false positive association
(usually 5%). In order to keep the probability of making
any false positive discovery below this probability
threshold, the individual P value thresholds for each
test need to be adjusted, resulting in a genome- or array-
wide significance threshold. This correction for multiple
testing can be achieved by common methods such as
Bonferroni correction (dividing the P value threshold by
the number of tests conducted) or a false discovery rate
correction [65, 66].
Tissue specificity
Given the prominent role epigenetic mechanisms play
in cellular differentiation, genome-wide epigenetic pro-
files tend to differ substantially between different tissues
and cell-types, matching the differences in function (e.g.,
fat storage in adipose tissue vs. synaptic transmission
performed by neurons). Different cellular functions
require particular sets of proteins acting in concert (i.e.,
pathways) and epigenetic mechanisms control which
genes are active in which cell-type and tissue-context.
Interestingly, epigenetic profiles can distinguish func-
tionally different brain regions [67] and cell-types
[68, 69]. Is disease-associated epigenetic dysregulation
tissue-specific? For example, are epigenetic correlates
of psychiatric diseases restricted to the brain? In some
disorders, including AN, it is less straightforward to
pinpoint the affected tissue of interest. AN is character-
ized by both psychiatric and metabolic features [6].
Therefore, one would ideally investigate epigenetic pro-
files in both brain tissue and metabolic tissues (e.g.,
adipose tissue, pancreas, liver, stomach, and the intes-
tine). The investigation of brain in particular, however,
poses considerable challenges and is typically only
possible in postmortem samples, which introduces addi-
tional complications for epigenetic studies (e.g., time
of death, cause of death, etc.). Nonetheless, carefully
designed, ethical discussions of organ donations with
patients and families are worthy of consideration.
Surrogate tissues
Although investigation of epigenetic profiles in the
disease-affected tissue is the gold standard in epigenetic
studies, it is also valuable to examine epigenetics in sur-
rogate peripheral tissues, including whole blood, epithe-
lial cells, and saliva. First, while epigenetic profiles are
highly tissue-specific and profiles observed in peripheral
tissues are not generally representative of epigenetic
variation in brain, specific genomic regions manifest high
levels of epigenetic covariation [67, 70, 71]. For example,
an existing online platform allows for the profiling of
DNA methylation covariation between whole blood and
multiple brain regions (//epigenetics.essex.ac.uk/bloodbra
in/). Second, while results emerging from epigenetic
studies from peripheral samples might not necessarily
reflect the epigenetic changes in disorder-relevant tissues,
they can still be used as potential biomarkers, and are
collected more readily and less invasively than the
affected tissue itself. Importantly, when analyzing whole
blood epigenetic profiles, the blood cell-type composition
also needs to be assessed. Blood is a heterogeneous
organ comprised of distinct cell types, fulfilling specific
tasks, such as oxygen transport, immune function, and
nutrient distribution. Because blood composition in
patients suffering from eating disorders differs from
controls [30], it is imperative to control for these differ-
ences in cell-type composition. If unaccounted for, epi-
genetic differences identified in an association scan could
be related purely to differences in cellular composition
rather than epigenetic dysregulation directly linked
to disease etiology and progression. Where blood cell
counts are not available, validated estimators of subcell
proportions based on large reference panels can be used;
i.e., cell-type proportions can accurately be estimated
using microarray-based DNA methylation data. This
also applies to other cell-types, and estimators based on
DNA methylation array data have been previously
reported for whole brain, buccal swabs, and saliva sam-
ples. These estimators require array-wide DNA methyla-
tion profiles and are therefore not applicable in candidate
gene studies [72].
Genome-wide integrated epigenetic studies
Many of the studies reviewed here use targeted sequen-
cing approaches, which only allow the investigation of
DNA methylation in limited genomic regions and ignore
information from the rest of the genome. This may
increase the chances for false positive reports via a




publication bias of positive findings. Genome-wide tech-
nologies are less prone to this phenomenon and allow for
the verification of previously reported differentially
methylated sites. While only whole genome bisulfite
sequencing allows full coverage of the entire genome,
array-based approaches like Illumina’s EPIC array, allow
widespread coverage of CpG sites in most genomic
regions and can be a more cost-effective solution.
All epigenetic studies of eating disorders published
to date focused on DNA methylation only. A host of
other sources of regulatory variation including other
DNA modifications, histone modifications, and non-coding
RNAs should also be investigated. Furthermore, to better
interpret the role of epigenetic modifications in disease,
it is important to understand their interactions with the
genetic sequence itself. Integrated analyses incorporating
genotypic, epigenetic, transcriptomic, and detailed envir-
onmental data are beginning to emerge, elucidating the
role of disease-associated epigenetic dysregulation in
specific genetic and environmental contexts. Increasingly
detailed maps of genetic and (multi)epigenetic profiles in
health and disease will be essential to improve our under-
standing of the molecular biological pathways implicated
in complex disease.
Eating disorder-specific considerations
In addition to these general recommendations for improv-
ing epigenetic research in disease epidemiology, there
are also a number of important eating disorder-specific
complexities to be considered.
Eating disorder-specific confounders
Because epigenetic modifications are dynamic and can be
altered by environmental influences, epigenetic association
studies are subject to a wide range of confounders. Con-
founding in EWAS is comparable to classic observational
epidemiological studies and ideally these confounders
are addressed in the study design in such a way that they
can be controlled for in the statistical analyses. For example,
age, sex, diet, micronutrients, medication, dietary supple-
ments, hormones, smoking, and alcohol consumption can
interact with an individual’s epigenetic profile, obfuscating
EWAS analyses (Fig. 2).
A large body of evidence confirms that diet composi-
tion can have an effect on an individual’s epigenetic
profile [73–77]. Eating and compensatory behaviors can
include binge eating and purging behaviors, abuse of diet
medication, laxatives, and diuretics altering fluid balance.
It is important to record their typical use, as well as the
frequencies and recency of use and, ideally, obtaining
blood levels of diet medications when possible. Both
indicated and off-label prescribed antidepressants, antic-
onvulsants, and atypical antipsychotics are used to control
accompanying symptoms observed in patients suffering
from eating disorders [78]. Dosage and intake should be
included in the analysis, ideally, blood levels should be
measured, and statistical analyses corrected for. This
strategy should also be followed for supplements, such as
vitamins and micronutrients, and hormones as patients
with eating disorders often show hormonal alterations,
such as high cortisol and low sex hormones [79, 80].
These types of hormones are direct ligands to so-called
promoters, enhancers, and silencers and, therefore,
influence gene expression and protein levels directly.
Weight differences between cases and controls should be
accounted for; however, if substantial between group
differences exist between cases and controls, disease and
weight-associated epigenetic variation will remain con-
voluted. One option in addressing this issue is using a
matched weight control group, potentially in addition to
normal weight controls, in order to tease apart epigenetic
correlates of eating disorder versus altered weight phe-
notypes. However, this approach may be limited because
constitutionally thin individuals rarely have a BMI as low
as patients suffering from severe AN. Environmental
toxins, such as smoking and alcohol, can have a profound
impact on the epigenome. For example, prevalence dif-
ferences in smoking between cases and controls have been
shown to confound the association between DNA
methylation and schizophrenia [14].
As with every observational study design, the causal
attribution of epigenetic associations in eating disorders is
extremely difficult. The epigenetic dysregulation
could potentially have causally contributed to the disease or
have arisen as a consequence of the disease, its symptoms
or even treatments, such as medication; [81] or, in a third
scenario, there could be a third factor driving both the
disease and the epigenetic alteration, which have no direct
link between one another. One important approach to
addressing causality is to consider temporal factors [26, 27].
A variety of chronologically variable factors should be
taken into account, such as age of disorder onset, duration
of illness, onset of menstrual disturbances, and duration of
amenorrhea (in women). Longitudinal sampling and within-
subject comparisons can help differentiate between sequelae
of starvation or overeating and epigenetic factors that con-
tribute to the liability to develop an eating disorder.
In addition to this, methods using genetic variants as
instrumental variables can improve causal inference.
In epigenetic epidemiology, Mendelian randomization is of
particular importance, exploiting genetic influences
on DNA methylation (mQTLs) to understand whether
phenotypic associations of DNA methylation are indeed
causal [82].





Epigenetic research in eating disorders is still in its
infancy, but initial results from pilot studies encourage
further and larger-scale investigation. Much like progress
in genomics, international collaborations are required to
amass adequately powered sample sizes to draw credible
conclusions from epigenetic investigations. Even more
importantly, careful study design is of vital importance
in epigenetics and can aid in avoiding potential pitfalls.
Robust, replicable results from carefully designed studies
have the potential to uncover the molecular biological
processes involved in disease onset and progression,
they may help characterize gene regulatory effects of non-
coding genetic variation, and, hopefully, give indications
into disease-relevant biological pathways which could
be addressed by therapeutic interventions. Clearly a
considerable amount of functional work is required in
follow-up of epigenetic association studies to better
understand the gene regulatory, cellular, and organismal
outcomes of epigenetic variation and derive potential
translational implications and therapeutic avenues. Even
non-functional disease-associated epigenetic variation
from peripheral tissue sources could, however, have use-
ful implications as biomarkers for risk and prognosis
assessment and for use in early diagnosis.
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femoral	 neck	 (-0.10	 g/cm2,	 CI	 95%:	 -0.15,	 -0.04,	 Q	 =	 0.001)	 even	 after	 weight	
recovery.	 Again,	 the	 post-treatment	 estimates	 have	 limited	 validity	 as	 they	were	
based	on	only	two	studies	with	31	AN	cases	and	insufficient	follow-up	duration.	The	





0.04)	and	body	 fat	percentage	 (lumbar	 spine;	βmetareg	 =	0.01,	p	 =	0.001)	between	
cases	 and	 controls	 (Supporting	 Information	Table	 S4).	 Cases	 and	 controls	 in	 our	
meta-analyses	were	age-	and	height-matched	(Supporting	Information	Figure	S2	&	
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Here we provide detailed information to illustrate that confounding due to population 
stratification or other reasons was minimal in our primary GWAS. Two relevant 
parameters were estimated using linkage-disequilibrium (LD) score regression29. Firstly, 
we estimated an LD intercept of 1.02 (s.e. = 0.01) for the meta-analysis and between 
0.98-1.03 for individual datasets (Supplementary Table 1). The LD score intercept is 
significantly greater than one, but is in line with the expected small levels of inflation 
caused by sample size and heritability described in Loh et al.59. A second measure, the 
attenuation ratio [(LDSC intercept – 1) / (mean χ2 – 1)] for the meta-analysis was 0.07 
(s.e. = 0.04) (Supplementary Fig. 1), also suggesting a lack of confounding. Together 
these suggest that deviation from the null was due to polygenic signal and not 
population structure or bias.  
 
The overall inflation of summary statistics genomewide or λGC for individual datasets 
post-QC ranged between 1.00-1.06 (Supplementary Table 1) and for the meta-analysis 
was 1.22 (Supplementary Fig. 1). Inflation of tests statistics is known to be due to a 
combination of polygenicity, uncorrected population stratification, and confounding. 
The larger λGC value observed for our GWAS meta-analysis is indeed expected at this 
sample size, trait polygenicity, and heritability59. The LD score regression method for 
GWAS of highly polygenic phenotypes such as anorexia nervosa and large sample sizes 
separates the polygenetic component (the slope) from population stratification and other 
systematic biases (estimated by the intercept and attenuation ratio) 29. 
 
Correcting for λGC in large GWAS samples of polygenic phenotypes can cause loss of 
signal and power, as evidenced by the LD intercept of the GWAS summary statistics 
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from the Genetic Investigation of Anthropometric Traits (GIANT) Consortium 2015 
body mass index (BMI) paper (0.65)60,61. Correction for λGC at the individual study level 
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  4.95%   1.13 [1.01, 1.24]
  2.27%   0.81 [0.55, 1.06]
  2.63%   0.89 [0.66, 1.12]
  2.22%   0.98 [0.72, 1.24]
  2.63%   1.13 [0.90, 1.36]
  2.58%   0.76 [0.53, 1.00]
  2.89%   1.09 [0.88, 1.31]
  2.29%   1.02 [0.76, 1.27]
  2.31%   1.25 [1.00, 1.50]
  2.36%   0.89 [0.64, 1.14]
  2.35%   1.05 [0.80, 1.30]
  2.46%   0.83 [0.59, 1.07]
  2.44%   1.03 [0.78, 1.27]
  2.28%   0.82 [0.57, 1.08]
  2.23%   0.93 [0.67, 1.19]
  2.57%   1.17 [0.94, 1.40]
  2.49%   0.86 [0.62, 1.10]
  1.77%   1.06 [0.76, 1.37]
  3.86%   1.08 [0.92, 1.24]
  4.87%   1.04 [0.93, 1.16]
  3.29%   1.08 [0.89, 1.27]
  2.79%   1.21 [0.99, 1.42]
  4.91%   1.08 [0.96, 1.19]
  1.42%   1.35 [1.00, 1.70]
  6.09%   0.98 [0.92, 1.05]
  2.19%   1.14 [0.88, 1.41]
  3.43%   1.01 [0.83, 1.19]
  1.26%   0.96 [0.58, 1.35]
  4.31%   1.35 [1.21, 1.49]
  2.98%   1.11 [0.90, 1.31]
  1.76%   1.33 [1.02, 1.64]
  4.97%   1.19 [1.08, 1.30]
  6.17%   1.08 [1.01, 1.14]



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Enhancer Andersson extend 500
H3K4me1 Trynka extend 500






UTR 5 UCSC extend 500




H3K4me3 Trynka extend 500
TFBS ENCODE extend 500
CTCF Hoffman extend 500
FetalDHS Trynka extend 500








Conserved LindbladToh extend 500
Repressed Hoffman extend 500
Enhancer Hoffman





Intron UCSC extend 500
Transcri Hoffman extend 500
H3K27ac PGC2 extend 500
H3K4me1 peaks Trynka
H3K9ac Trynka extend 500
PromoterFlanking Hoffman extend 500
Coding UCSC extend 500




Promoter UCSC extend 500
TSS Hoffman
UTR 3 UCSC extend 500
UTR 5 UCSC
H3K9ac peaks Trynka
DGF ENCODE extend 500
DHS Trynka extend 500
Conserved LindbladToh
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Coefficient − log10(p − value) Pr(hg
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Brain Nucleus accumbens basal ganglia
Brain Caudate basal ganglia
Brain Amygdala
Brain Cortex
Brain Anterior cingulate cortex BA24
Brain Frontal Cortex BA9
Brain Putamen basal ganglia
Brain Cerebellar Hemisphere
Brain Cerebellum





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Oxytocin and Vasopressin Expressing Neurons
Oligodendrocytes
Endothelial mural




























Dataset no PGC abbreviation Total N 
1 chop 4,600 
 
Dataset no PGC abbreviation Total N 
2 fin1 633 
 
 
Dataset no PGC abbreviation Total N 




Dataset no PGC abbreviation Total N 





Supplementary Figure 16. Polygenic risk score (PRS) leave-one-out analysis: results for each cohort. PRS was constructed with  
the leave-one-out method from a GWAS with all datasets excluding the target dataset. Then, PRS was used to predict change in 
residualized phenotype score for anorexia nervosa (AN) risk in the target dataset (shown as the center value and an error bar which 
represents the 95% confidence interval of this estimate). The decile with the lowest PRS (i.e., subjects whose AN PRS is in the  
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Dataset no PGC abbreviation Total N 
17 w12 961 
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Dataset no PGC abbreviation Total N 
21 w16 974 
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Dataset no PGC abbreviation Total N 
25 w20 1,002 
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Dataset no PGC abbreviation Total N 
29 w24 2,688 
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(𝑃+(𝐴𝐵, 𝐶𝐷) − 𝑚(𝐴𝐵, 𝐶𝐷))@	
	
The	jackknife	estimate	of	the	difference	between	the	two	correlations	m(AB,CD)	can	




𝑚(𝐴𝐵, 𝐶𝐷) − 𝜃C
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intervals	 (CI	95%).	After	 the	age	of	19	heritabilities	 are	 represented	 for	 a	whole	






















and	 the	 black	 line	 indicates	 the	 null	 hypothesis	 of	 no	 true	 association.	 Different	
colours	depict	 the	 three	different	GWAS:	both	 sexes	 (yellow),	 female	 (red),	male	
(blue).	Deviation	from	the	expected	p	value	distribution	is	evident	only	in	the	tail	










and	 the	 black	 line	 indicates	 the	 null	 hypothesis	 of	 no	 true	 association.	 Different	















Supplementary	 Figure	 4b.	 Manhattan	 plot	 of	 the	 meta-analyzed	 genome-wide	




























Supplementary	Figure	6a.	Partitioned	heritability	by	10	cell	 type	groups	 for	 fat	
free	mass	(FFM)	in	females.	The	black	dashed	lines	at	−log10(P)	=	2.3	is	the	cutoff	for	
Bonferroni	 significance.	 CNS	 =	 central	 nervous	 system,	 SNP	 =	 single	 nucleotide	
polymorphism.	
	
Supplementary	Figure	6b.	Partitioned	heritability	by	10	cell	 type	groups	 for	 fat	
free	mass	(FFM)	in	males.	The	black	dashed	lines	at	−log10(P)	=	2.3	is	the	cutoff	for	






Supplementary	Figure	6c.	Partitioned	heritability	by	10	cell	 type	groups	 for	 fat	
free	mass	(FFM)	in	the	meta-analyzed	GWAS.	The	black	dashed	lines	at	−log10(P)	=	















Supplementary	 Table	 2	 |	 Exclusion	 criteria	 by	 International	 Statistical	
Classification	 of	 Diseases	 (ICD-10),	 British	 National	 Formulary	 (BNF),	 and	 UK	
Biobank	variable	
	












		 Meta-analyzed	 Female	 Male	
Number	(%)	 155,961	 70,700	(45%)	 85,261	(55%)	
Age,	years	 54.9	±	8.1	 54.8	±	8.0	 55.0	±	8.2	
Height,	cm	 170.4	±	9.3	 163.0	±	6.2	 176.4	±	6.7	
Weight,	kg	 78.1	±	15.1	 69.6	±	12.6	 85.1	±	13.2	
Body	mass	index,	kg/m2	 27.0	±	4.2	 26.2	±	4.6	 27.4	±	3.8	
Waist	circumference,	cm	 89.4	±	12.6	 82.3	±	11.3	 95.3	±	10.3	
Hip	circumference,	cm	 102.5	±	8.1	 102.0	±	9.3	 103.0	±	6.9	
Waist-to-hip	ratio	 0.9	±	0.1	 0.8	±	0.1	 0.9	±	0.1	
Body	fat,	%	 29.3	±	8.2	 35.3	±	6.7	 24.4	±	5.5	
Fat	mass,	kg	 23.0	±	8.5	 25.3	±	9.1	 21.2	±	7.5	
Fat-free	mass,	kg	 55.1	±11.6	 44.4	±	4.6	 63.9	±	7.4	
Socioeconomic	 status,	
Townsend	Deprivation	Index	 -1.6	±	2.9	 -1.7	±	2.8	 -1.7	±	2.9	
Data	are	n	(%),	or	mean	(SD).	
	 	 	 	
Alcohol	consumption	 Freq	 %	Total	 %	Total	Cum.	
Daily	or	almost	daily	 34,830	 22.3	 22.3	
Three	or	four	times	a	week	 41,952	 26.9	 49.2	
Once	or	twice	a	week	 43,055	 27.6	 76.8	
One	to	three	times	a	month	 16,314	 10.5	 87.3	
Special	occasions	only	 12,952	 8.3	 95.6	
Never	 6,858	 4.4	 100.0	
Total	 155,961	 100	 100	
	 	 	 	
Tobacco	smoking	 Freq	 %	Total	 %	Total	Cum.	
No	 142,141	 91.1	 91.1	
Only	occasionally	 9,465	 6.1	 97.2	
Yes,	on	most	or	all	days	 4,355	 2.8	 100.0	






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary	 Fig.	 1	 |	 Putative	 causal	 associations	 of	 exposures	 psychiatric	
disorders	and	behavioural	traits	with	outcomes	body	composition	traits.		
	
Supplementary	 Fig.	 2a	 |	 Sex-specific	 genetic	 correlations	 of	 body	 composition	
traits	 and	 physical	 activity	 with	 psychiatric	 disorders	 and	 behavioural	 traits	 for	
females	only.	
	
Supplementary	 Fig.	 2b	 |	 Sex-specific	 genetic	 correlations	 of	 body	 composition	
traits	 and	 physical	 activity	 with	 psychiatric	 disorders	 and	 behavioural	 traits	 for	
males	only.	
	
Supplementary	 Fig.	 3a	 |	 Sex-specific	 genetic	 correlations	 of	 glycemic	 traits	 of	
psychiatric	disorders	and	behavioural	traits	for	females	only.	
	



















Supplementary	 Fig.	 2a	 |	 Sex-specific	 genetic	 correlations	 of	 body	 composition	 traits	 (n	 =	 up	 to	
155,961)	and	physical	activity	(n	=	up	to	66,224)	with	psychiatric	disorders	(n	=	up	to	35,585)	and	
behavioural	 traits	 (n	=	up	 to	122,428)	 for	 females	only.	The	autosomal	genetic	correlations	were	
calculated	 by	 bivariate	 linkage	 disequilibrium	 score	 regression	 (LDSC).	 Colored	 bars	 represent	
genetic	 correlations,	 error	 bars	 depict	 standard	 errors	 (SE)	 and	 asterisks	 indicate	 statistically	
significant	genetic	correlations	with	p	values	less	than	α	=0.0003.	This	threshold	was	calculated	via	
the	 identification	 of	 the	 number	 of	 independent	 tests	 using	matrix	 decomposition	 of	 the	 genetic	






Supplementary	Fig.	 2b	 |	 Sex-specific	 genetic	 correlations	 of	 body	 composition	 traits	 (n	 =	 up	 to	
155,961)	and	physical	activity	(n	=	up	to	66,224)	with	psychiatric	disorders	(n	=	up	to	45,699)	and	
behavioural	 traits	 (n	 =	 up	 to	 95,140)	 for	 males	 only.	 The	 autosomal	 genetic	 correlations	 were	
calculated	 by	 bivariate	 linkage	 disequilibrium	 score	 regression	 (LDSC).	 Colored	 bars	 represent	
genetic	 correlations,	 error	 bars	 depict	 standard	 errors	 (SE)	 and	 asterisks	 indicate	 statistically	
significant	genetic	correlations	with	p	values	less	than	α	=0.0003.	This	threshold	was	calculated	via	
the	 identification	 of	 the	 number	 of	 independent	 tests	 using	matrix	 decomposition	 of	 the	 genetic	








The	 autosomal	 genetic	 correlations	 were	 calculated	 by	 bivariate	 linkage	 disequilibrium	 score	
regression	(LDSC).	Colored	bars	represent	genetic	correlations,	error	bars	depict	standard	errors	
(SE)	 and	 asterisks	 indicate	 statistically	 significant	 genetic	 correlations	with	 p	 values	 less	 than	 α	











(LDSC).	 Colored	 bars	 represent	 genetic	 correlations,	 error	 bars	 depict	 standard	 errors	 (SE)	 and	
asterisks	indicate	statistically	significant	genetic	correlations	with	p	values	less	than	α	=0.0002.	This	







5.2	 Members	 of	 the	 ADHD	 Working	 Group	 of	 the	 Psychiatric	 Genomics	
Consortium	
	and	others	involved	in	the	generation	of	the	ADHD	data	used	in	the	current	
study	
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